Annual Author Index

Following is the author index for volume 163 of the *Journal*, which covers all material from January 2006 through December 2006. The *Journal* no longer prints a subject index. Two-letter abbreviations are used for months. The complete citation for each article is listed under the name of the first author. Coauthors are listed alphabetically with a cross-reference to the first author; cross-references containing multiple first author names separated by semicolons indicate multiple articles by the coauthor. Entries other than Reviews and Overviews and New Research are given the following designations: Editorial (editorial), Images in Neuroscience (image, neuro), Introspections (introspections), Treatment in Psychiatry (treatment in psychiatry), Clinical Case Conference (case conf), Images in Psychiatry (image, psych), Book Forum (bk rev), Letters to the Editor (letter), Official Actions (off acts), and Supplement (suppl). Corrections are cited with the articles to which they refer. Readers can also use the Journal's website (ajp.psychiatryonline.org) to search by author, issue, subject, section, or keyword.

A

à Campo J see van Os J
Aalto S see Hirvonen J
Aarø LE see Mykletun A
Abbacchi A see Constantino JN
Abel KM see Webb RT
Aboujaoude E see Koran LM
Abraham PF, Shirley ER: New mnemonic for depressive symptoms (letter). Fe 329–330
Abramson R: Opiate treatment for patients in chronic non-cancer pain (letter). Jy 1299
Abramson RK see Rabionet R
Adams CE see Leonard S
Adams J see Adler CM
Adamson JJ see Faraone SV
Addington D see McGlashan TH
Addington J see McGlashan TH
Adetunji B see Basil B
Adetunji B, Mathews M, Osinowo T, Williams A: Risperidone for the core symptom domains of autism (letter). Mr 551
Adewuya AO: Early postnatal mood as a risk factor for postnatal depression in Nigerian women. Au 1435–1437
Adler CM, Adams J, DelBello MP, Holland SK, Schmithorst V, Levine A, Jarvis K, Strakowski SM: Evidence of white matter pathology in bipolar disorder adolescents experiencing their first episode of mania: a diffusion tensor imaging study. Fe 322–324
Adler DA, McLaughlin TJ, Rogers WH, Chang H, Lapitsky L, Lerner D: Job performance deficits due to depression. Se 1569–1576
Adler L see Kessler RC
Adler L: bk rev, Berman AL, Jobes DA, Silverman MM: Adolescent Suicide: Assessment and Intervention, Second Edition. Je 1116–1117
Afifi TO, Cox BJ, Sareen J: Gambling-related problems are chronic and persist for the majority of individuals with a lifetime diagnosis of pathological gambling (letter). Jy 1297
Agerbo E see Eaton WW
Aggen SH see Fanous AH
Ahmari SE see Merrill DB
Akiskal HS see Kessler RC
Alagbe O see Pace TWW
Alda M see Krüger S
Aleardi M see Moore CM
Allen A see Hollander E
Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL: Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Fe 272–275
Allison KC see Lundgren JD; O'Reardon JP
Allison SE, von Wahlde L, Shockley T, Gabbard GO: The development of the self in the era of the Internet and role-playing fantasy games (case conf). Mr 381–385
Alpert JE see Fava M; McGrath PJ; Nierenberg AA
Altinbas K see Oral ET
Altshuler LL see Leverich GS; Yaeger D
Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, Keck PE Jr, Frye MA, Kupka R, McElroy SL, Grunze H, Kitchen CMR, Post R: Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Fe 313–315
Alvarez CA, Mascarenas C, Timmerman I: Increasing psychosis in a patient switched from Clozaril to generic clozapine (letter). Ap 746
Aman MG see McDougle CJ
Amat JA, Bronen RA, Saluja S, Sato N, Zhu H, Gorman DA, Royal J, Peterson BS: Increased number of subcortical hyperintensities on MRI in children and adolescents with Tourette's syndrome, obsessive-compulsive disorder, and attention deficit hyperactivity disorder. Je 1106–1108
Ambery F see Page LA
Amendoeira MC, Cavalcanti MT: Nisae Magalhães da Silveira (1905–1999) (image, psych). Au 1348
American Board of Psychiatry and Neurology: 2005 annual report of the American Board of Psychiatry and Neurology, Inc. (off acts). Au 1460–1463
American Board of Psychiatry and Neurology: Report on the 2005 examinations (off acts). Au 1464–1477
American Psychiatric Association: APA council reports (off acts). Fe 337–352
American Psychiatric Association: Highlights of the 2006 Annual Meeting (off acts). Oc 1849–1857
American Psychiatric Association: Practice guideline for the psychiatric evaluation of adults, second edition. Je Suppl 1 (correction, Oc 1843)
American Psychiatric Association: Practice guideline for the treatment of patients with eating disorders, third edition. Jy Suppl 1 (correction, Se 1649)
American Psychiatric Association: Practice guideline for the treatment of patients with substance use disorders, second edition. Au Suppl 1 (correction, Oc 1843)
American Psychiatric Association: Reports to the membership (off acts). Se 1655–1663
Ames M see Kessler RC
Amital D, Vishne T, Rubinow A, Levine J: Observed effects of creatine monohydrate in a patients with depression and fibromyalgia (letter). Oc 1840–1841
Amlo S see Høglend P
Amunts K see Schneider F
Anckarsäter H, Stahlberg O, Larson T, Hakansson C, Jutblad S-B, Niklasson L, Nydén A, Wentz E, Westergren S, Cloninger CR, Gillberg C, Rastam M: The impact of ADHD and autism spectrum disorders on temperament, character, and personality development. Jy 1239–1244
Anderson GM see Gorman DA
Anderson S see Riccardi P
Andersson G see Carlbring P
Andreasen NC see Paz RD
Andreasen NC: Farewell, thou child of my right hand (editorial). Ja 1–2
Andres C see Laumonnier F
Andrews J, Wang L, Csernansky JG, Gado MH, Barch DM: Abnormalities of thalamic activation and cognition in schizophrenia. Mr 463–469
Anjum A see White T
Ansari MS see Riccardi P
Antonarakis SE see Glaser B
Antoni MH, Wimberly SR, Lechner SC, Kazi A, Sifre T, Urcuyo KR, Phillips K, Smith RG, Petronis VM, Guellati S, Wells KA, Blomberg B, Carver CS: Reduction of cancer-spe-

cific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. Oc 1791–1797
Anvar J see Nickel MK
Aperia A, Greengard P: Dopamine receptor response to NMDA stimulation (image, neuro). Oc 1682
Appelbaum PS see Dunn LB
Appelbaum PS: The Council on Psychiatry and Law (off acts). Fe 346–347
Appelbaum PS: Violence and mental disorders: data and public policy (editorial). Au 1319–1321
Appleby L see Webb RT
Apter A see Nemets H
Arango C see Artaloytia JF
Arango V see Parsey RV
Araya R, Flynn T, Rojas G, Fritsch R, Simon G: Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. Au 1379–1387
Arcement J see Parsey RV
Arciniegas DB: New-onset bipolar disorder in late life: a case of mistaken identity (treatment in psychiatry). Fe 198–203
Ardekani BA see Lim KO
Arnold LE see McDougle CJ
Arranz B see Reynolds GP
Arroyo B see Breen G
Arsenault NJ see Woodward SH
Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, Prieto D, Palomo T: Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Mr 488–493
Aryal S see Pavuluri MN
Ashley-Koch AE see Rabionet R
Assalian P see Rosen R
Attiullah N see Zimmerman M
Augustyns I see Reyes M
Aulakh JS see Yohanan M
Austin KL see Valenstein M
Aydt EE see Skosnik PD

B

Babbar JP: Frontline treatment of combat stress reaction (letter). Je 1111
Babulas V, Factor-Litvak P, Goetz R, Schaefer CA, Brown AS: Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. My 927–929
Bachler E see Nickel MK
Backes V see Schneider F
Badaracco MA see Freedman R
Badaracco MA: bk rev, Kandel ER: Psychiatry, Psychoanalysis, and the New Biology of Mind. Ja 165–166
Bai YM, Lin C-C, Chen J-Y, Lin C-Y, Su T-P, Chou P: Association of initial antipsychotic response to clozapine and long-term weight gain. Jy 1276–1279
Bak M see van Os J
Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Jansons S, Wilhelm K: A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. No 1934–1942
Baker DG see Geracioti TD Jr
Baker JD see Allen MH
Baker RW see Perlis RH; Tohen M
Balasubramani GK see Trivedi MH
Baldassarra L see Beitchman JH
Baldwin R see Riccardi P
Balon R: bk rev, Evans DL, Foa EB, Gur RE, Hendin H, O'Brien CP, Seligman MEP, Walsh BT, eds: Treating and Preventing Adolescent Mental Health Disorders: What We Know and What We Don't Know. A Research Agenda for Improving the Mental Health of Our Youth. Ap 753–754
Balon R: bk rev, Roberts LW, Hilty D, eds: Handbook of Career Development in Academic Psychiatry and Behavioral Sciences. Au 1455–1456
Balon R: SSRI-associated sexual dysfunction (treatment in psychiatry). Se 1504–1509
Bammer R see Cascio C
Bangerter K see Rosen R
Banov MD see Tohen M
Banzato CEM: bk rev, Sadler JZ: Values and Psychiatric Diagnosis. My 943–944
Barch DM see Andrews J
Barkley R see Kessler RC
Barr HM, Bookstein FL, O'Malley KD, Connor PD, Huggins JE, Streissguth AP: Binge drinking during pregnancy as a predictor of psychiatric disorders on the Structured Clinical Interview for DSM-IV in young adult offspring. Je 1061–1065
Barry JJ see Stonnington CM
Barry S see Kanayama G
Barton BA see Klein DJ
Barzman DH, DelBello MP: Topiramate for co-occurring bipolar disorder and disruptive behavior disorders (letter). Au 1451–1452
Basil B, Mathews M, Adetunji B, Budur K: The CATIE Study (letter). Mr 555
Bass NJ see Kalsi G
Bauer MS see Nierenberg AA; Polsky D
Bauer MS: Managing the academic-industrial complex (letter). De 2193
Beardslee WR see Reinherz HZ
Beasley C, Meijer D, Kerwin R, Cotter D, Everall I, Price J: Author retraction. Au 1454
Bebbington PE see Torres AR
Beckmann C see Winterer G
Beekman ATF see Schoevers RA
Beitchman JH, Baldassarra L, Mik H, De Luca V, King N, Bender D, Ehtesham S, Kennedy JL: Serotonin transporter polymorphisms and persistent, pervasive childhood aggression. Je 1103–1105
Belhadj A see Laumonnier F
Belloni DR see Wishart HA
Belmaker RH see Levine J; Nemets H
Benazzi F: Antidepressant-induced or clinician-induced suicidality in depression? (letter). Se 1644
Bender D see Beitchman JH
Bender DS see Gunderson JG
Benedek EP: bk rev, Ozonoff S, Rogers SJ, Hendren RL, eds: Autism Spectrum Disorders: A Research Review for Practitioners. Fe 332–333
Benitez J see Fitzgerald PB
Benjamin L see Seritan AL
Benjamin L: Balance beam (introspections). Je 979–980
Benjamin LS: Review of Interpersonal Reconstructive Therapy (letter). Ja 161–162
Bennett T see Gabbard GO
Berber M see Rosen R
Berg KC see Lundgren JD
Berger SR see Reinherz HZ
Bergh C see Södersten P
Berglund P see Borges G
Bergström J see Rück C
Berk M, Dodd S, Malhi GS: Depression and mania in mixed states (image, psych). Jy 1160
Berthoz S see Godart N
Berv D see Wagner KD
Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P: Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907. Se 1580–1587
Bhaumik DK see Gibbons RD
Bhugra D see Torres AR
Biederman J see Faraone SV; Hirshfeld-Becker DR; Kessler RC; Moore CM; Spencer TJ
Biederman J, Petty C, Fried R, Fontanella J, Doyle AE, Seidman LJ, Faraone SV: Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Oc 1730–1738
Biggs MM see Fava M; McGrath PJ; Trivedi MH
Bilker WB see Schneider F; Siegel SJ
Bimson B see Mathews CA
Birnbaum H see Kessler RC
Bjerkeset O see Mykletun A
Black DO see Altshuler LL
Blackwell AD see Chamberlain SR
Blaine J see Roll JM
Blair RJR see Monk CS
Blankertz L see Cook JA
Blaser DG: bk rev, Cabeza R, Nyberg L, Park D: Cognitive Neuroscience of Aging: Linking Cognitive and Cerebral Aging. Mr 560–561
Blazer DG: bk rev, Galanter M: Spirituality and the Healthy Mind: Science, Therapy, and the Need for Personal Meaning. Je 1115–1116
Bleich S see Hillemacher T
Bloch S see Kissane DW
Block JJ: Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis (letter). Oc 1838
Blomberg B see Antoni MH
Bloom A see Murphy K
Blow FC see Valenstein M
Blumenfield M: Report of the Speaker-Elect (off acts). Se 1660
Blyler C see Cook JA

Bodnar LM, Sunder KR, Wisner KL: Treatment with selective serotonin reuptake inhibitors during pregnancy: deceleration of weight gain because of depression or drug? (case conf). Je 986–991 (correction, Oc 1843)
Boerescu D see Zimmerman M
Bøgwald K-P see Høglend P
Bohman S see Carlbring P
Bonab AA see Spencer TJ
Bonuccelli U see Lattanzi L
Bookstein FL see Barr HM
Boovariwala A see Meyer JH
Borges G, Medina-Mora ME, Wang PS, Lara C, Berglund P, Walters E: Treatment and adequacy of treatment of mental disorders among respondents to the Mexico National Comorbidity Survey. Au 1371–1378
Borjigin J see Snyder SH
Borras L see Mohr S
Bosch P, van den Noort M: Terrorism and health services utilization (letter). De 2198
Boss V see Vaiva G
Bossie CA see Gharabawi GM
Bourke DL see Sandson NB
Bouvy PF see van Strater ACP
Bowden CL see Allen MH; Tohen M
Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR: Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Jy 1199–1201
Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD: Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Mr 418–425
Bracha Z see Nemets H
Bradford J-ME see Merrill DB
Bradley BP see Monk CS
Bradley R see Westen D
Bradshaw JL see Silk TJ
Brady K, Sinha R: Reply to Kudler; Monterrubio, Solowij: Chronic stress and adaptation (letter). Mr 553
Brammer M see Smith AB
Bramon E see Dempster EL; McDonald C
Brandt P-Y see Mohr S
Brecher M see Harvey PD
Brecht ML see Roll JM
Breen G, Prata D, Osborne S, Munro J, Sinclair M, Li T, Staddon S, Dempster D, Sainz R, Arroyo B, Kerwin RW, St. Clair D, Collier D: Association of the dysbindin gene with bipolar affective disorder. Se 1636–1638
Breier A see McGlashan TH
Bremner JD see Vermetten E
Brenner C: Jacob A Arlow (1912–2004) (image, psych). Se 1518
Brensinger CM see Siegel SJ
Brent DA see Zalsman G
Brewer EJ see Fehnel CR
Brewster S see Forty L
Briault S see Laumonnier F
Bronen RA see Amat JA
Brotchie H see Parker G
Brown AS see Babulas V
Brown AS, Schaefer CA, Quesenberry CP Jr, Shen L, Susser ES: No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? De 2178–2180
Brown E see Perlis RH
Brown SM see Hariri A
Brown TL see Fitzgerald PB
Brown WH see Lee K-H
Bruder GE see Taylor BP
Brugha TS see Torres AR
Brune CW, Kim S-J, Salt J, Leventhal BL, Lord C, Cook EH Jr: 5-HTTLPR genotype-specific phenotype in children and adolescents with autism. De 2148–2156
Brunet A see Vaiva G
Brunt S see Carlbring P
Bruun RD see Mathews CA
Buchanan RW: Important steps in the development of cognitive-enhancing drugs in schizophrenia (editorial). No 1867–1869
Buchsbaum MS see Haznedar MM
Buckholtz JW see Tan H-Y
Buckley PJ, Michels R, Mackinnon RA: Changes in the psychiatric landscape (editorial). My 757–760
Budman CL see Mathews CA
Budur K see Basil B
Buhrman M see Carlbring P
Buhtz F see Grabe HJ
Buitelaar J see Reyes M
Bulik C see Kaye WH; Pope HG Jr
Bullmore ET see McDonald C
Burdick KE see DeRosse P
Burgdorf A see Dowling NM
Burgmair W see Engstrom EJ
Burke AK see Zalsman G
Burke-Miller JK see Cook JA
Burns J see Stoddard FJ
Bursztajn HJ see Gopal AA
Buschmann W see Nickel MK
Bustillo J see Paz RD
Butler PD see Lim KO
Butler PD, Hoptman MJ, Nierenberg J, Foxe JJ, Javitt DC, Lim KO: Visual white matter integrity in schizophrenia. No 2011–2013
Butler T see Epstein J
Byrne M see Eaton WW

C

Caesar S see Forty L
Cahard D see Laumonnier F
Calabrese JR see Bowden CL; Nierenberg AA; Tohen M
Callicott JH see Tan H-Y; Winterer G
Cannon TD see Hirvonen J
Carboon I see Creamer M
Carlbring P, Bohman S, Brunt S, Buhrman M, Westling BE, Ekselius L, Andersson G: Remote treatment of panic disorder: a randomized trial of Internet-based cognitive behavioral therapy supplemented with telephone calls. De 2119–2125
Carlson GA see Margulies DM
Carnes PJ see Gold MS
Carpenter LL see Geracioti TD Jr
Carpenter WT Jr see Freedman R
Carpenter WT Jr: Targeting schizophrenia research to patient outcomes (editorial). Mr 353–355
Carr VJ see Baker A
Carter CS see Siegle GJ
Carter CS, Pine DS: Polishing the windows of the mind (editorial). My 761–763
Carter CS: Understanding the glass ceiling for functional outcome in schizophrenia (editorial). Mr 356–358
Carter D see Misri S
Cartwright C see Haznedar MM
Carver CS see Antoni MH
Cascio C, Styner M, Smith RG, Poe MD, Gerig G, Hazlett HC, Jomier M, Bammer R, Piven J: Reduced relationship to cortical white matter volume revealed by tractography-based segmentation of the corpus callosum in young children with developmental delay. De 2157–2163
Casey BJ, Durston S: From behavior to cognition to the brain and back: what have we learned from functional imaging studies of attention deficit hyperactivity disorder? (editorial). Je 957–960
Caspi A see Ehrensaft MK; Kim-Cohen J
Cassano GB see Lattanzi L
Cather C see Freudenreich O
CATIE Study Investigators see Lieberman JA; McEvoy JP; Rosenheck RA; Stroup TS
Cattapan-Ludewig K See Feth N
Cavalcanti MT see Amendoeira MC
Cavaleri MA see Smith MV
Cayton GA see Hirshfeld-Becker DR
Cea CD See Fisher CB
Cerra D: Trimipramine for refractory panic attacks (letter). Mr 548
Chaabouni H see Laumonnier F
Challacombe F see Stein A
Chamberlain SR, Fineberg NA, Blackwell AD, Robbins TW, Sahakian BJ: Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Jy 1282–1284
Chang H see Adler DA
Chapple B see McDonald C
Charney DS see Monk CS; Zarate CA Jr
Chavez MR see Fenton WS
Chen C-C see Faraone SV
Chen C-Y see Eaton WW; Faraone SV
Chen G see Monk CS
Chen J see Xiao Z
Chen J-Y see Bai YM
Chen WJ see Faraone SV
Chen Y see McGrath PJ
Cheng J see McGrath PJ
Cheong J: The Council on Aging (off acts). Fe 339–340
Chou FH-C see Faraone SV
Chou JC-Y see Tohen M
Chou P see Bai YM
Choudhury K see Kalsi G
Christopher EJ see Jiang W
Chueh C-M see Faraone SV
Chung EC see Jang JH
Chusid J see Epstein J
Ciccone PE see Spencer TJ
Cipriani A, Pretty H, Hawton K, Geddes JR: Reply to Connemann: Lithium and suicidality revisited (letter). Mr 550
Clark DB see Tarter RE
Cloninger CR see Anckarsäter H
Colleaux L see Laumonnier F
Collier D see Breen G; Dempster EL
Compton WM, Conway KP, Stinson FS, Grant BF: Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991–1992 and 2001–2002. De 2141–2147
Conley R see Paz RD

Connemann BJ: Lithium and suicidality revisited (letter). Mr 550
Conners CK see Kessler RC
Connor PD see Barr HM
Constant J see Laumonnier F
Constantino JN, Lajonchere C, Lutz M, Gray T, Abbacchi A, McKenna K, Singh D, Todd RD: Autistic social impairment in the siblings of children with pervasive developmental disorders. Fe 294–296
Conway KP see Compton WM
Cook EH Jr see Brune CW
Cook IA see Hunter AM
Cook JA, Razzano LA, Burke-Miller JK, Pickett-Schenk SA, Grey DD, Lehman AF, McFarlane WR, Gold PB, Leff HS, Blyler C, Toprac MG, Blankertz L, Shafer M: Reply to Rosenheck: Integration of mental health care and supported employment (letter). My 940
Cooper C see Forty L
Cooper S see Stein A
Coppola R see Winterer G
Corey-Lisle P see Olfson M
Corley RP see Young SE
Cortese BM, Uhde TW: Immobilization panic (letter). Au 1453–1454
Cotter D see Beasley C
Cottingham EM see Klein DJ
Covell NH see Essock SM
Cowen P see Bhagwagar Z
Cox BJ see Afifi TO
Coyne JC, Marcus SC: Health disparities in care for depression possibly obscured by the clinical significance criterion. Se 1577–1579
Cozza SJ see Grieger TA
Craddock N see Forty L
Craske M see Roy-Byrne P
Crawford TJ see Ettinger U
Creamer M, Carboon I, Forbes AB, McKenzie DP, McFarlane AC, Kelsall HL, Sim MR: Psychiatric disorder and separation from military service: a 10-year retrospective study. Ap 733–734
Crijns HJGM see de Jonge P
Crilly JF see Lamberti JS
Cromwell J see Drozd EM
Crow S see Lundgren JD
Crow SJ see Pope HG Jr
Crowe RP see Mondimore FM
Crowley TJ see Young SE
Csernansky JG see Andrews J
Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC: Plasma cortisol and progression of dementia in DAT subjects. De 2164–2169
Cubero P see Artaloytia JF
Cuccaro ML see Rabionet R
Cuijpers P see Schoevers RA
Cullen N see Walder DJ
Cunningham-Williams R see Grant JE
Cunnington R see Silk TJ
Curran S see Murphy DGM
Curtis D see Kalsi G

D

Dackis CA see O'Brien CP
Dager SR see Friedman SD; Hwang J
Dahl AA see Mykletun A
Dahoun SP see Glaser B
Daly E see Murphy DGM; Page LA
Daly RC see Richards M
Daoud SZ see Paz RD
Daskalakis ZJ see Fitzgerald PB
Dave S see Forty L
Daversa MT see Gunderson JG
Davidson J, Eisen MJ: Rudolf Steiner (1861–1925) (image, psych). No 1897
Davidson PW See Fisher CB
Davies M see Gorman DA
Davis CE see Lieberman JA; McEvoy JP; Stroup TS
Davis J see Heres S
Davis JM see Freedman R
Davis JM, Marder SR, Tamminga CA: Switch or stay? (editorial). De 2029–2030
Davis KL see Haroutunian V
Davis L see McGrath PJ
Davis SM see Essock SM; Lieberman JA; McEvoy JP; Rosenheck RA; Stroup TS
Dawant B see Riccardi P
De Bruin ML see Wilting I
de Castella A see Fitzgerald PB
De Jesus G see Zarate CA Jr
de Jonge P: Reply to Thombs, Grace, Ziegelstein: Do symptom dimensions of depression following myocardial infarction related differently to physical health indicators and cardiac prognosis? (letter). Jy 1296
de Jonge P, Ormel J, van den Brink RHS, van Melle JP, Spijkerman TA, Kuijper A, van Veldhuisen DJ, van den Berg M, Honig A, Crijns HJGM, Schene AH: Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Ja 138–144
De Luca V see Beitchman JH
Dean L see Forty L
Debbane M see Glaser B
Deeg DJH see Schoevers RA
Deeley PQ see Page LA
Degn B see Kalsi G
deGruy FV III: A note on the partnership between psychiatry and primary care (editorial). Se 1487–1489
Dehning S see Seemüller F
Dekker J see Schoevers RA
DelBello MP see Adler CM; Barzman DH
Delespaul P see van Os J
DeLong GR see Rabionet R
Demirkiran S see Oral ET
Demler O see Kessler RC; Wang PS
Dempster D see Breen G
Dempster EL, Toulopoulou T, McDonald C, Bramon E, Walshe M, Wickham H, Sham PC, Murray RM, Collier DA: Episodic memory performance predicted by the 2bp deletion in exon 6 of the "alpha 7-like" nicotinic receptor subunit gene. Oc 1832–1834
Denicoff KD see Leverich GS
Denicoff KK see Zarate CA Jr
DePaulo JR see Lin P-I; Mondimore FM
DePaulo JR Jr: Bipolar disorder treatment: an evidence-based reality check (editorial). Fe 175–176
DeRago AC see Vaillant GE
DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, Kucherlapati R, Malhotra AK: Dysbindin genotype and negative symptoms in schizophrenia. Mr 532–534
Desarkar P, Thakur A, Sinha VK: Aripiprazole-induced acute dystonia (letter). Je 1112–1113
Detke HC see Tohen M
DeVane CL see Loughhead AM
Devos P see Vaiva G
Dietz MB see Lamberti JS
DiGiacomo J see Neimark G
DiMaria J see Roll JM
Dinzeo TJ see Docherty NM
Dixon V see Murphy K
Docherty NM, Strauss ME, Dinzeo TJ, St-Hilaire A: The cognitive origins of specific types of schizophrenic speech disturbances. De 2111–2118
Dodd S see Berk M
Doi N, Usui C: Are high-risk haplotypes in DTNBP1 and NRG1 resistance genes for schizophrenia? (letter). My 940–941
Dong H see Csernansky JG
Dorahy M see van der Hart O
Doshi JA see Polsky D
Dougherty DD see Spencer TJ
Dougherty LR see Laptook RS
Dougherty M see Moore CM
Dowling FG, Moynihan G, Genet B, Lewis J: A peer-based assistance programs for officers with the New York City Police Department: report of the effects of Sept. 11, 2001. Ja 151–153
Dowling NM, Megna JL, Burgdorf A, Yashaswi V: Lingual lesions with orally disintegrating risperidone (letter). Oc 1841–1842
Doyle AE see Biederman J
Dracheva S see Haroutunian V
Drake JE see Stoddard FJ
Drake RE see Goldman HH
Drozd EM, Cromwell J, Gage B, Maier J, Greenwald LM, Goldman HH: Patient casemix classification for Medicare psychiatric prospective payment. Ap 724–732
Drukker M see van Os J
Druss RG: Piano sonata in A major (introspections). Fe 195–197
D'Souza J see Wagner KD
Duberstein PR see Pinquart M
Dubovsky SL: bk rev, Hales RE, Yudofsky SC, Chew RH: What Your Patients Need to Know About Psychiatric Medications. Ja 166
Ducrocq F see Vaiva G
Duggal HS, Mendhekar DN: Atypical antipsychotics, tardive dyskinesia, and D2 receptors (letter). Au 1449–1450
Dunn LB, Nowrangi MA, Palmer BW, Jeste DV, Saks ER: Assessing decisional capacity for clinical research or treatment: a review of instruments. Au 1323–1334
Dunn LB, Palmer BW, Keehan M, Jeste DV, Appelbaum PS: Assessment of therapeutic misconception in older schizophrenia patients with a brief instrument. Mr 500–506
Dunner DL see Hwang J
Durst R see Raskin S
Durston S see Casey BJ
Dvorin S see Lamberti JS
Dyck IR see Gunderson JG

E

Eastwood SL, Harrison PJ: Cellular basis of reduced cortical reelin expression in schizophrenia. Mr 540–542

Eaton JS Jr: Feldman MD: Playing Sick? Untangling the Web of Munchausen Syndrome, Munchausen by Proxy, Malingering, and Factitious Disorder. Fe 334–335

Eaton WW, Byrne M, Ewald H, Mors O, Chyen C-Y, Agerbo E, Mortensen PB: Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Mr 521–528

Edelsohn GA: Hallucinations in children and adolescents: considerations in the emergency setting (treatment in psychiatry). My 781–785

Eerdekens M see Reyes M

Eersels J see Murphy DGM

Egan G see Silk TJ

Egan MF see Marenco S; Tan H-Y; Winterer G

Egberts TCG see Wilting I

Egger C see Nickel MK

Egleston PN see Lee K-H

Ehlers A: More evidence for the role of persistent dissociation in PTSD (letter). Je 1112

Ehrensaft MK, Moffitt TE, Caspi A: Is domestic violence followed by an increased risk of psychiatric disorders among women but not among men? a longitudinal cohort study. My 885–892

Ehrlichman H see Taylor BP

Ehtesham S see Beitchman JH

Eisen MJ see Davidson J

Ekhator NN see Geracioti TD Jr

Ekholm J see DeRosse P; Lencz T

Ekselius L see Carlbring P

Ekstrom RD see Golden RN

El Mallakh RS, Karippot A: Chronic depression in bipolar disorder (treatment in psychiatry). Au 1337–1341

Elbogen EB see Swanson JW

Elia M see Laumonnier F

Eliez S see Glaser B; Woodward SH

Ell P see Murphy DGM

Ellis SP see Zalsman G

Elmquist J, Zigman J, Lutter M: Molecular determinants of energy homeostasis (image, neuro) Jy 1137

Emsley R, Rabinowitz J, Medori R: Time course for antipsychotic treatment response in first-episode schizophrenia. Ap 743–745

Emslie GJ see Wagner KD

Endo T see Kripke DF

Engel CC see Grieger TA

Engstrom EJ, Weber MM, Burgmair W: Emil Wilhelm Magnus Georg Kraepelin (1856–1926) (image, psych). Oc 1710

Enns MW see Lam RW

Epstein I see McGlashan TH

Epstein J, Pan H, Kocsis JH, Yang Y, Butler T, Chusid J, Hochberg H, Murrough J, Strohmayer E, Stern E, Silbersweig DA: Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Oc 1784–1790

Erenberg G see Mathews CA

Erickson CK, Wilcox RE: Please, not "addiction" in DSM-V (letter). No 2015–2016

Erickson K see Lysne DH

Erlandsson K see Murphy DGM

Ernst CL see Roffman JL

Ernst M see Monk CS

Ersner H see Kuroki N

Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA: Effectiveness of switching antipsychotic medications. De 2090–2095

Eth S see Shalev AY

Ettelt S see Grabe HJ

Ettinger U, Picchioni M, Hall M-H, Schulze K, Toulopoulou T, Landau S, Crawford TJ, Murray RM: Antisaccade performance in monozygotic twins discordant for schizophrenia: The Maudsley Twin Study. Mr 543–545

Everall I see Beasley C

Evgeny S see Salganik I

Ewald H see Eaton WW

F

Faber RJ see Koran LM

Factor-Litvak P see Babulas V

Fagan AM see Csernansky JG

Fagiolini A see Frank E; Lattanzi L

Fainsinger RL, Thai V, Frank G, Fergusson J: What's in a word? addiction versus dependence in DSM-V (letter). No 2014–2015

Fairburn CG see Stein A

Falkai P see Grabe HJ

Fancy S see Bhagwagar Z

Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, Kedler KS, O'Neill FA, Walsh D: Reply to Doi, Usui: Are high-risk haplotypes in DTNBP1 and NRG1 resistance genes for schizophrenia? (letter). My 940–941

Faraone SV see Biederman J; Hirshfeld-Becker DR; Kessler RC

Faraone SV, Biederman J, Spencer T, Mick E, Murray K, Petty C, Adamson JJ, Monuteaux MC: Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Oc 1720–1729

Faraone SV, Hwu H-G, Liu C-M, Chen WJ, Tsuang M-M, Liu S-K, Shieh M-H, Hwang T-J, Ou-Yang W-C, Chen C-Y, Chen C-C, Lin J-J, Chou FH-C, Chueh C-M, Liu W-M, Hall M-H, Su J, Van Eerdewegh P, Tsuang MT: Genome scan of Han Chinese schizophrenia families from Taiwan: confirmation of linkage to 10q22.3. Oc 1760–1766

Farmer A see Forty L

Farrell M see Torres AR

Farrow TFD see Lee K-H

Fartacek R see Nickel MK

Fauman MA: Defining a DSM infrastructure (editorial). No 1873–1874

Fava M see McGrath PJ; Nierenberg AA; Rush AJ; Trivedi MH

Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Jy 1161–1172

Favazza A: bk rev, Rusesabagina P, Zoellner T: An Ordinary Man. De 2202–2203

Fazel S, Grann M: Reply to Pinta: Limitations of study on violent crime and mental illness (letter). De 2194

Fazel S, Grann M: The population impact of severe mental illness on violent crime. Au 1397–1403

Fehnel CR, Brewer EJ: Munchausen's syndrome with 20-year follow-up (letter). Mr 547

Fekete C see Lechan RM

Fenger M see Rasmussen HB

Fenton WS, Chavez MR: Medication-induced weight gain and dyslipidemia in patients with schizophrenia (treatment in psychiatry). Oc 1697–1704

Fergusson J see Fainsinger RL

Ferrando SJ see Rabkin JG

Ferron J see Swanson JW

Fertuzinhos S see Reynolds GP

Feth N, Cattapan-Ludewig K, Sirot EJ: Electric sensations: neglected symptom of escitalopram discontinuation (letter). Ja 160

Filbey F see McDonald C

Findling RL see Wagner KD

Fineberg NA see Chamberlain SR

Fink M, Taylor MA: Catatonia: subtype or syndrome in DSM? (editorial). No 1875–1876

Fireman M see Matthews AM

First MB: Beyond clinical utility: broadening the DSM-IV research appendix to include alternative diagnostic constructs (editorial). Oc 1679–1681

First MB, Zimmerman M: Including laboratory tests in DSM-V diagnostic criteria (editorial). De 2041–2042

Fischman AJ see Spencer TJ

Fishbain DA, Gallagher RA: Comments on "Prescription drug dependence and evolving beliefs about chronic pain management" (letter). De 2194

Fisher AD see Loughhead AM

Fisher CB, Cea CD, Davidson PW, Fried AL: Capacity of persons with mental retardation to consent to participate in randomized clinical trials. Oc 1813–1820

Fisher RS see Stonnington CM

Fitzgerald PB, Benitez J, de Castella A, Daskalakis ZJ, Brown TL, Kulkarni J: A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Ja 88–94

Fitzmaurice GM see Reinherz HZ

Flaherty LT: The Council on Children, Adolescents, and Their Families (off acts). Fe 340–341

Flashman LA see Wishart HA

Flegenheimer WV: The psychotherapy of sexually impulsive patients (letter). Ap 748

Flynn T see Araya R

Flynn WR: bk rev, Harris JC: Intellectual Disability: Understanding Its Development, Causes, Classification, Evaluation, and Treatment. Oc 1846–1847

Fontaine M see Vaiva G

Fontanella J see Biederman J

Foote B, Smolin Y, Kaplan M, Legatt ME, Lipschitz D: Prevalence of dissociative disorders in psychiatric outpatients. Ap 623–629
Forbes AB see Creamer M
Forman RF, Woody GF McLellan T, Lynch KG: The availability of web sites offering to sell opioid medications without prescriptions. Jy 1233–1238
Forty L, Jones L, Macgregor S, Caesar S, Cooper C, Hough A, Dean L, Dave S, Farmer A, McGuffin P, Brewster S, Craddock N, Jones I: Familiality of postpartum depression in unipolar disorder: results of a family study. Se 1549–1553
Foxe JJ see Butler PD
Frampton CMA see Mulder RT
Frank E see Phillips ML
Frank E, Gonzalez JM, Fagiolini A: The importance of routine for preventing recurrence in bipolar disorder (treatment in psychiatry). Je 981–985 (corrections, Se 1648, Oc 1843)
Frank G see Fainsinger RL
Frankenburg FR see Zanarini MC
Franklin C see Pliszka SR
Frederick BB see Woodward SH
Freedman R see Gabbard GO; Lewis DA
Freedman R: bk rev, Gayford M: The Yellow House: Van Gogh, Gauguin, and Nine Turbulent Weekes in Arles. De 2202
Freedman R: Nancy C. Andreasen, M.D., Ph.D.: editor emeritus perfectus (editorial). Ja 3–4
Freedman R, Carpenter WT Jr, Davis JM, Goldman HH, Tamminga CA, Thomas M: The costs of drugs for schizophrenia (editorial). De 2031–2033
Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA: 2006 in review (editorial). De 2037–2040
Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga C, Patterson SL, McIntyre JS, Goldman HH, Yudofsky SC, Hales RE, Rapaport MH, Hales D, Krajeski J, Kupfer DJ, Badaracco MA, Scully JH Jr: Conflict of interest, round 2 (editorial). Se 1481–1483
Freimer NB see Mathews CA
Frenkiel-Fishman S see Shalev AY
Freudenreich O, Cather C, Holt D: Stimulant misuse in college for "pseudo-attention deficit disorder" during schizophrenia prodrome (letter). No 2019
Freudenreidh O see Kontos N
Freyberger HJ see Grabe HJ
Fried AL See Fisher CB
Fried R see Biederman J
Friedman M see Zimmerman M
Friedman MJ: Posttraumatic stress disorder among military returnees from Afghanistan and Iraq (treatment in psychiatry). Ap 586–593
Friedman SD see Hwang J
Friedman SD, Mathis CM, Hayes C, Renshaw P, Dager SR: Brain pH response to hyperventilation in panic disorder: preliminary evidence for altered acid-base regulation. Ap 710–715
Frieling H see Hillemacher T
Friis S see Melle I
Fritsch R see Araya R
Frosch WA: bk rev, Menza M, Marsh L, eds: Psychiatric Issues in Parkinson's Disease: A Practical Guide. Au 1456–1457
Frost-Pineda K see Gold MS
Frumin M see Onitsuka T
Frye MA see Altshuler LL; Leverich GS
Fujita K see Tanii H
Funke B see DeRosse P

G

Gabbard GO see Allison SE; Seritan AL
Gabbard GO: bk rev, Yalom I: The Schopenhauer Cure: A Novel. Je 1118
Gabbard GO: When is transference work useful in dynamic psychotherapy? (editorial). Oc 1667–1669
Gabbard GO, Bennett T: Reply to Flegenheimer; Koblenzer: The psychotherapy of sexually impulsive patients (letter). Ap 749
Gabbard GO, Freedman R: Psychotherapy in the Journal: what's missing? (editorial). Fe 182–184
Gado MH see Andrews J
Gage B see Drozd EM
Gagliardi JP see Jiang W
Galanter M: bk rev, Strain EC, Stitzer ML, eds: The Treatment of Opioid Dependence. Se 1650
Galbraith J see Lundgren JD
Galfalvy H see Sublette ME
Galina P see Salganik I
Gallagher RA see Fishbain DA
Ganesan V see Hunter MD
Ganzini L: Physician-assisted suicide (letter). Je 1109–1110
Garavan H see Murphy K
Gardner CO see Kendler KS
Gary AP: The Good Samaritan? (introspections). De 2057–2058
Gatz M see Kendler KS
Gau SS-F see Lin L
Gaynes BN see Golden RN
Geddes JR see Cipriani A
Genet B see Dowling FG
Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB: Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Ap 637–643
Gerig G see Cascio C; Gilmore JH
Gersons BPR see Storosum JG
Gharabawi GM, Bossie CA, Zhu Y: New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol (letter). My 938–939
Gibbons RD, Hur K, Bhaumik DK, Mann JJ: The relationship between antidepressant prescription rates and rate of early adolescent suicide. No 1898–1904
Gibson NA see Parker G
Gil FP see Nickel MK
Gilbert JR see Rabionet R
Gillberg C see Anckarsäter H
Gilliéron C see Mohr S
Gilmore JH, Lin W, Gerig G: Fetal and neonatal brain development (image, neuro). De 2046
Gispen-de Wied CC see Storosum JG
Glahn DC see Pliszka SR
Glaser B, Debbane M, Hinard C, Morris MA, Dahoun SP, Antonarakis SE, Eliez S: No evidence for an effect of COMT Val158Met genotype on executive function in patients with 22q11 deletion syndrome. Mr 537–539
Glick HA see Polsky D
Glozier N see Mykletun A
Godart N, Berthoz S, Perdereau F, Jeammet P: Comorbidity of anxiety with eating disorders and OCD (letter). Fe 326
Goetz R see Babulas V
Goghari VM see Khorram B
Gold LH: bk rev, Charles SC, Frisch PR: Adverse Events, Stress, and Litigation: A Physician's Guide. Ja 166–167
Gold LH: Report of the Committee of Tellers (off acts). Se 1662–1663
Gold LH, Metzner JL: Psychiatric employment evaluations and the Health Insurance Portability and Accountability Act. No 1878–1882
Gold MS, Frost-Pineda K, Carnes PJ: Depression-related improvement with vardenafil for erectile response (letter). Au 1449
Gold PB see Cook JA
Goldapple K see Krüger S
Goldberg TE see Marenco S
Golden RN, Gaynes BN, Hamer RH, Ekstrom RD: Reply to Kripke, Tuunainen, Endo: Benefits of light treatment for depression (letter). Ja 163
Goldman D see Lencz T; Parsey RV; Zalsman G
Goldman HH see Drozd EM; Freedman R
Goldman HH, Drake RE: Mood disorders and workplace performance: half a loaf (editorial). Se 1490–1491
Goldney RD: On intercountry adoptions (letter). Ja 162
Goldney RD: Suicide risk in placebo-controlled trials of bipolar disorder (letter). Fe 329
Goldstein BI, Herrmann N, Shulman KI: Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Fe 319–321
Goldstein BI, Levitt AJ: Further evidence for a developmental subtype of bipolar disorder defined by age at onset: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Se 1633–1636
Goldstein JM see Walder DJ
Golinelli D see Roy-Byrne P
Gonzalez JM see Frank E
Good KP, Whitehorn D, Rui Q, Milliken H, Kopala LC: Olfactory identification deficits in first-episode psychosis may predict patients at risk for persistent negative and disorganized or cognitive symptoms. My 932–933

Gopal AA, Bursztajn HJ: tbk rev, Palermo GB, Kocsis RN: Offender Profiling: An Introduction to the Sociopsychological Analysis of Violent Crime. Mr 559–560
Gopalakrishnan R see Thangadurai P
Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK: Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Mr 494–499
Gorman DA see Amat JA
Gorman DA, Zhu H, Anderson GM, Davies M, Peterson BS: Ferritin levels and their association with regional brain volumes in Tourette's syndrome. Jy 1264–1272
Gorman JM: bk rev, Shapiro J: A Year in the Life of William Shakespeare 1599. De 2200–2202
Goudemand M see Vaiva G
Grabe HJ, Ruhrmann S, Ettelt S, Buhtz F, Hochrein A, Schulze-Rauschenbach S, Meyer K, Kraft S, Reck C, Pukrop R, Freyberger HJ, Klosterkötter J, Falkai P, John U, Maier W, Wagner M: Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects. No 1986–1992
Grace SL see Thombs BD
Grann M see Fazel S
Grant BF see Compton WM
Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A: Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Fe 303–312
Grasby P see Bhagwagar Z
Gray T see Constantino JN
Greden JF see Valenstein M
Green MF see Sergi MJ
Green RDJ see Lee K-H
Greenberg P see Kessler RC
Greengard P see Aperia A
Greenhill LL see Kessler RC
Greenspan RJ see Kendler KS
Greenwald LM see Drozd EM
Grey DD see Cook JA
Grieger TA, Cozza SJ, Ursano RJ, Hoge C, Martinez PE, Engel CC, Wain HJ: Posttraumatic stress disorder and depression in battle-injured soldiers. Oc 1777–1783
Grilo CM see Gunderson JG
Grinshpoon A see Levav I
Gross R see Kolevzon A
Grossman J: bk rev, Oldham JM, Skodol AE, Bender DS, eds: The American Psychiatric Publishing Textbook of Personality Disorders. Mr 558–559
Grunau RE see Misri S
Grunze H see Altshuler LL; Leverich GS; Seemüller F
Guardino M see Terleph TA
Guellati S see Antoni MH
Guérin P see Laumonnier F
Guerin SJ see Wishart HA
Gunderson JG, Daversa MT, Grilo CM, McGlashan TH, Zanarini MC, Shea MT, Skodol AE, Yen S, Sanislow CA, Bender DS, Dyck IR, Morey LC, Stout RL: Predictors of 2-year outcome for patients with borderline personality disorder. My 822–826
Gunderson JG, Weinberg I, Daversa MT, Kueppenbender KD, Zanarini MC, Shea MT, Skodol AE, Sanislow CA, Yen S: Descriptive and longitudinal observations of the relationship of borderline personality disorder and bipolar disorder. Jy 1173–1178 (correction, Oc 1843)
Gunduz-Bruce H see Lencz T; Robinson DG
Gur RC see Schneider F; Siegel SJ
Gur RE see Schneider F; Siegel SJ
Gurling H see Kalsi G
Gutheil T see Norris DM
Gyulai L see Perlis RH

H

Ha TH see Jang JH
Haahr U see Melle I
Haas AP see Hendin H
Habel U see Schneider F
Haberstick BC see Young SE
Hadar H see Shalev AY
Hadzi-Pavlovic D see Parker G
Haile M see Baker A
Haines JL see Rabionet R
Hakansson C see Anckarsäter H
Halayem M see Laumonnier F
Hales D see Freedman R
Hales RE see Freedman R
Hall M-H see Ettinger U; Faraone SV
Halperin J see Taylor BP
Hamann J, Leucht S, Kissling W: Reply to Preda: Do schizophrenia patients want to be involved in their treatment? (letter). My 937
Hamer RH see Golden RN
Hamilton CA see Hamilton NG
Hamilton NG, Hamilton CA: Reply to Ganzini: Physician-assisted suicide (letter). Je 1110
Hammerness P see Moore CM
Hammond KG see Roberts LW
Hardan AY, Muddasani S, Vemulapalli M, Keshavan MS, Minshew NJ: An MRI study of increased cortical thickness in autism. Jy 1290–1292
Hariri A, Brown SM: Serotonin (image, neuro). Ja 12
Hariri AR, Lewis DA: Genetics and the future of clinical psychiatry (editorial). Oc 1676–1678
Harkavy-Friedman JM: Can early detection of psychosis prevent suicidal behavior? (editorial). My 768–770
Haroutunian V, Katsel P, Dracheva S, Davis KL: The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: downregulated in multiple brain regions in schizophrenia. Oc 1834–1837
Harpold T see Moore CM
Harral EM see Pavuluri MN
Harrison PJ see Eastwood SL
Hartmann L: bk rev, Hibbs ED, Jensen PS, eds: Psychosocial Treatments for Child and Adolescent Disorders: Empirically Based Strategies for Clinical Practice, Second Edition. Jy 1302–1303
Harvey PD see Bowie CR; Keefe RSE
Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M: Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. No 1918–1925
Hashimoto T, Lewis DA: BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Mr 534–537
Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R: Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Ap 689–696
Hastings RS see Parsey RV
Hatchett AD see Zacher JL
Hauser P see Matthews AM
Hawkins JW see Yohanan M
Hawkins KA see McGlashan TH
Hawton K see Cipriani A
Hayes C see Friedman SD
Hazlett EA see Haznedar MM
Hazlett HC see Cascio C
Haznedar MM, Buchsbaum MS, Hazlett EA, LiCalzi EM, Cartwright C, Hollander E: Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders. Jy 1252–1263
Heaton RK see Bowie CR
Hedeker D see Kassem L
Heim CM see Pace TWW
Hemmingsen R see Rasmussen HB
Hendin H: bk rev, Simon RI, Hales RE, eds: The American Psychiatric Publishing Textbook of Suicide Assessment and Management. Fe 331
Hendin H, Haas AP, Maltsberger JT, Koestner B, Szanto K: Problems in psychotherapy with suicidal patients. Ja 67–72
Henin A see Hirshfeld-Becker DR
Henn-Haase C see Neylan TC
Hennen J see Zanarini MC
Henningsen P see Rief W
Heo M see O'Reardon JP
Herbener ES see Pavuluri MN
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Fe 135–194
Herrera LD see Mathews CA
Herrmann N see Goldstein BI
Hertzmann L see Stein A
Heru AM: Family psychiatry: from research to practice. Je 962–968
Heruc G see Parker G
Hettema JM, Neale MC, Myers JM, Prescott CA, Kendler KS: A population-based twin study of the relationship between neuroticism and internalizing disorders. My 857–864
Hewitt JK see Young SE
Heyerdahl O see Høglend P
Heyman I see Micali N
Hibbeln JR see Sublette ME
Hierholzer R: Remission rates for depression in STAR*D study (letter). Jy 1293
Hierholzer RW see Neylan TC

Hietala J see Hirvonen J
Higgins ST: Extending contingency management to the treatment of methamphetamine use disorders (editorial). No 1870–1872
Hill KP: Free lunch? (editorial). Ap 569–570
Hill SK see Pavuluri MN
Hillemacher T, Bleich S, Kornhuber J, Frieling H: Hair loss as a side effect of lamotrigine treatment (letter). Au 1451
Hiller W see Rief W
Hilty DM: bk rev, High WM Jr, Sander AM, Struchen MA, Hart KA, eds: Rehabilitation for Traumatic Brain Injury. Oc 1845–1846
Hinard C see Glaser B
Hines P see Olfson M
Hinz R see Bhagwagar Z
Hirayasu Y see Kuroki N
Hirschfeld RM see Allen MH
Hirschfeld RMA see Kessler RC
Hirschfeld RMA: Reply to Moreira-Almeida, Pietrobon: Does olanzapine have any antidepressant effect? (letter). Oc 1839
Hirshfeld-Becker DR, Biederman J, Henin A, Faraone SV, Cayton GA, Rosenbaum JF: Laboratory-observed behavioral disinhibition in the young offspring of parents with bipolar disorder: a high-risk pilot study. Fe 265–271
Hirvonen J, van Erp TGM, Huttunen J, Aalto S, Någren K, Huttunen M, Lönnqvist J, Kaprio J, Cannon TD, Hietala J: Brain dopamine D1 receptors in twins discordant for schizophrenia. Oc 1747–1753
Hjern A see Lindblad F
Hochberg H see Epstein J
Hochrein A see Grabe HJ
Hodo DW: bk rev, Dadock BJ, Kaplan HI: Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Eighth Edition. Au 1458 (correction. De 2199)
Hoffman RE see McGlashan TH
Hoge C see Grieger TA
Høglend P, Amlo S, Marble A, Bøgwald K-P, Sørbye Ø, Sjaastad MC, Heyerdahl O: Analysis of the patient-therapist relationship in dynamic psychotherapy: an experimental study of transference interpretations. Oc 1739–1746
Hokfelt T, Kuteeva E: Substance P: a neuropeptide (image, neuro). Ap 578
Holbert S see Laumonnier F
Holland SK see Adler CM
Hollander E see Grant JE; Haznedar MM
Hollander E, Allen A: Is compulsive buying a real disorder, and is it really compulsive? (editorial). Oc 1670–1672
Holt D see Freudenreich O
Holtzman DM see Csernansky JG
Holwerda NJ see Wilting I
Honer WG see Khorram B
Honig A see de Jonge P
Hoogendijk WJG: bk rev, Swaab DF: The Human Hypothalamus: Basic and Clinical Aspects (volumes I and II). Ap 754–755
Hoop J see Roberts LW
Hoptman MJ see Butler PD; Lim KO
Horn PS see Geracioti TD Jr
Horowitz MJ: bk rev, Clarkin JE, Yeomans FE, Kernberg OF: Psychotherapy for Borderline Personality: Focusing on Object Relations. My 944–945
Hough A see Forty L
Houle S see Meyer JH
Howard M see Zlotnick C
Howell HB see Smith MV
Howes MJ see Kessler RC
Howes OD: Compulsions in depression: stalking by text message (letter). Se 1642
Howland RH see Trivedi MH
Hsiao JK see Lieberman JA; McEvoy JP; Rosenheck RA; Stroup TS
Hu X see Parsey RV; Zalsman G
Huang Y-y see Parsey RV; Zalsman G
Hudson JI see Kanayama G; Pope HG Jr
Huggins JE see Barr HM
Huguelet P see Mohr S
Hunt JP see Scheeringa MS
Hunter AM, Leuchter AF, Morgan ML, Cook IA: Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Au 1426–1432
Hunter MD see Lee K-H
Hunter MD, Ganesan V, Wilkinson ID, Spence SA: Impact of modafinil on prefrontal executive function in schizophrenia. De 2184–2186
Hur K see Gibbons RD
Hurford MO see Neimark G
Hutto B see Perea E
Huttunen J see Hirvonen J
Huttunen M see Hirvonen J
Hwang J, Lyoo IK, Dager SR, Friedman SD, Oh JS, Lee JY, Kim SJ, Dunner DL, Renshaw PF: Basal ganglia shape alterations in bipolar disorder. Fe 276–285
Hwang T-J see Faraone SV
Hwu H-G see Faraone SV

I

Insel T: Beyond efficacy: the STAR*D trial (editorial). Ja 5–7
Insel T, Volkow N, Li T-K: The view from NIH (special article). De 2043–2045
Irani F see Siegel SJ

J

Jacob KS see Gopalakrishnan R; Thangadurai P
Jang DP see Jang JH
Jang JH, Kwon JS, Jang DP, Moon W-J, Lee J-M, Ha TY, Chung EC, Kim IY, Kim SI: A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder. Jy 1202–1207
Jansons S see Baker A
Jarvis K see Adler CM
Javitt DC see Butler PD; Lim KO
Jaworski JM see Rabionet R
Jeammet P see Godart N
Jefferson JW: bk rev, Stein DJ, Kupfer DJ, Schatzberg AF, eds: The American Psychiatric Publishing Textbook of Mood Disorders. Oc 1844
Jenkins R see Torres AR
Jeste DV see Dunn LB
Jetzinger E see Heres S
Jiang W: Reply to Penland: Lipids, hormones, and gastric bypass (letter). Je 1113–1114
Jiang W, Gagliardi JP, Raj YP, Silvertooth EJ, Christopher EJ, Krishnan KRR: Acute psychotic disorder after gastric bypass surgery: differential diagnosis and treatment (case conf). Ja 15–19
Jin R see Kessler RC; Shear K
Joa I see Melle I
Johannesen JO see Melle I
Johansen L see Streltzer J
John JK see Gopalakrishnan R
John U see Grabe HJ
Johnson B see Streltzer J
Johnston D see Rosenberg PB
Jolesz FA see Kuroki N
Jomier M see Cascio C
Jones DW see Winterer G
Jones HM see Uher R
Jones I see Forty L
Jones L see Forty L
Joyce PR see Mulder RT
Juszczak E see Stein A
Jutblad S-B see Anckarsäter H
Juurlink DN: Reply to Benazzi: Antidepressant-induced or clinician-induced suicidality in depression? (letter). Se 1644–1645
Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA: The risk of suicide with selective serotonin reuptake inhibitors in the elderly. My 813–821
Jyothi KS see Thangadurai P

K

Kagan J see Stoddard FJ
Kallio A see Grant JE
Kaloupek DG see Woodward SH
Kalsi G, McQuillin A, Degn B, Lundorf MD, Bass NJ, Lawrence J, Choudhury K, Puri V, Nyegaard M, Curtis D, Mors O, Kruse T, Kerwin S, Gurling H: Identification of the Slynar gene (AY070435) and related brain expressed sequences as a candidate gene for susceptibility to affective disorders through allelic and haplotypic association with bipolar disorder on chromosome 12q24. Oc 1767–1776
Kampman K see O'Brien CP
Kanas N: Group therapy with schizophrenia patients (letter). My 937–938
Kanayama G, Barry S, Hudson JI, Pope HG Jr: Body image and attitudes toward male roles in anabolic-androgenic steroid users. Ap 697–703
Kane JM see DeRosse P; Lencz T; Robinson DG
Kane JM: Tardive dyskinesia circa 2006 (editorial). Au 1316–1318
Kanes SJ see Siegel SJ
Kang JW see Keefe RSE
Kaplan M see Foote B
Kaplan P see Nickel MK
Kaprio J see Hirvonen J
Kapur S see Remington G
Karippot A see El Mallakh RS
Kassem L, Lopez V, Hedeker D, Steele J, Zandi P, NIMH Genetics Initiative Bipolar Disorder Consortium, McMahon FJ: Familiality of polarity at illness onset in bipolar affective disorder. Oc 1754–1759
Katabira E see Nakimuli-Mpungu E
Katsel P see Haroutunian V

Kaufman J see Murphy K
Kaye WH, Bulik C, Thornton L, Plotnicov K, Price Foundation Collaborative Investigators: Reply to Godart, Berthoz, Perdereau, Jeammet; Micali Heyman; Södersten, Bergh: Comorbidity of anxiety with eating disorders and OCD (letter). Fe 327–329
Kazi A see Antoni MH
Keck PE Jr see Altshuler LL; Leverich GS
Keefe RSE see Lieberman JA; McEvoy JP; Rosenheck RA; Stroup TS
Keefe RSE, Poe M, Walker TM, Kang JW, Harvey PD: The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Mr 426–432
Keehan M see Dunn LB
Keith SJ: Are we still talking to our patients with schizophrenia? (editorial). Mr 362–364
Kellogg S see Roll JM
Kelly KI see Sule A
Kelsall HL see Creamer M
Kendler KS see Fanous AH; Hettema JM
Kendler KS: Reflections on the relationship between psychiatric genetics and psychiatric nosology. Jy 1138–1146
Kendler KS: Reply to Rietschel, Propping, Nöthen: The impact of genetics on psychiatric nosology (letter). De 2198
Kendler KS, Gardner CO, Prescott CA: Toward a comprehensive developmental model for major depression in men. Ja 115–124
Kendler KS, Gatz M, Gardner CO, Pedersen NL: A Swedish national twin study of lifetime major depression. Ja 109–114
Kendler KS, Greenspan RJ: The nature of genetic influences on behavior: lessons from "simpler" organisms. Oc 1683–1694
Kendrick K see Misri S
Kennedy JL see Beitchman JH
Kenny ET see Miller JM
Kerwin R see Beasley C; Breen G; Murphy DGM
Kerwin S see Kalsi G
Keshavan MS see Hardan AY; Rao A
Kessler R see Riccardi P
Kessler RC see Shear K; Wang PS
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Ap 716–723
Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RMA, Jin R, Merikangas KR, Simon GE, Wang PS: Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Se 1561–1568
Ketter TA see Bowden CL; Nierenberg AA; Perlis RH
Kettler C see Nickel MK
Keyes BB see Xiao Z
Khadivi A see Robinson DG
Khantzian EJ: bk rev, Petry NM: Pathological Gambling: Etiology, Comorbidity, and Treatment. My 945–946
Khorram B, Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Goghari VM, Smith GN, Honer WG: Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine. No 2005–2007
Khorram B, Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Goghari VM, Smith GN, Honer WG: Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine. No 2005–2007 (correction, De 2199)
Khurshid KA: A tale of two cities (introspections). Au 1335–1336
Kikinis R see Kuroki N
Kim IY see Jang JH
Kim M see Swanson JW
Kim SI see Jang JH
Kim S-J see Brune CW
Kim SJ see Hwang J
Kim-Cohen J, Caspi A, Rutter M, Tomás MP, Moffitt TE: The caregiving environments provided to children by depressed mothers with or without an antisocial history. Je 1009–1018
Kimble MO see Woodward SH
King N see Beitchman JH
King-Hele SA see Webb RT
Kingdon D see Turkington D
Kinkead B see Geracioti TD Jr
Kirisci L see Tarter RE
Kirmayer L see Miresco MJ; Sharpe M
Kissane DW, McKenzie M, Bloch S, Moskowitz C, McKenzie DP, O'Neill I: Family focused grief therapy: a randomized controlled trial in palliative care and bereavement. Jy 1208–1218
Kissling W see Hamann J; Heres S
Kitchen CMR see Altshuler LL
Kleber HD see Miller JM
Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. De 2072–2079
Klein DN see Laptook RS
Klein DN, Shankman SA, Rose S: Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. My 872–880
Klein RG see Terleph TA
Kleinman A see Patel V
Kline NA: Revisiting once upon a time (introspections). Jy 1147–1148
Klosterkötter J see Grabe HJ
Knobler HY see Kolevzon A
Koblenzer J: The psychotherapy of sexually impulsive patients (letter). Ap 748–749
Koch K see Schneider F
Kocsis JH see Epstein J
Koestner B see Hendin H
Kohler CG see Siegel SJ
Kohn R see Vicente B
Kolevzon A, Weiser M, Gross R, Lubin G, Knobler HY, Schmeidler J, Silverman JM, Reichenberg A: Effects of season of birth on autism spectrum disorders: fact or fiction? Jy 1288–1290
Kontos N, Freudenreich O, Querques J: Using a medical model with psychotic patients (letter). Se 1646–1647
Kopala LC see Good KP; Khorram B
Kopp A see Juurlink DN
Koran LM, Faber RJ, Aboujaoude E, Large MD, Serpe RT: Estimated prevalence of compulsive buying behavior in the United States. Oc 1806–1812
Kornhuber J see Hillemacher T
Kowatch RA see Wagner KD
Kraft S see Grabe HJ
Krajeski J see Freedman R
Kripke DF, Tuunainen A, Endo T: Benefits of light treatment for depression (letter). Ja 162–163
Krishnan GP see Skosnik PD
Krishnan KRR see Jiang W
Kroenke K see Sharpe M
Krokstad S see Mykletun A
Krüger S, Alda M, Young LT, Goldapple K, Parikh S, Mayberg HS: Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings. Fe 257–264
Kruse T see Kalsi G
Kruszewski SP: Euphorigenic and abusive properties of modafinil (letter). Mr 549
Kucherlapati R see DeRosse P
Kudler H: Chronic stress and adaptation (letter). Mr 552–553
Kueppenbender KD see Gunderson JG
Kuhlenshmidt HA see Skosnik PD
Kuijper A see de Jonge P
Kulkarni J see Fitzgerald PB
Kupfer DJ see Freedman R; Rush AJ
Kupfer DJ: The Council on Research (off acts). Fe 350–351
Kupka R see Altshuler LL; Leverich GS
Kuroki N see Onitsuka T
Kuroki N, Shenton ME, Salisbury DF, Hirayasu Y, Onitsuka T, Ersner H, Yurgelun-Todd D, Kikinis R, Jolesz FA, McCarley RW: Middle and inferior temporal gyrus gray matter volume in first-episode schizophrenia: an MRI study. De 2103–2110
Kuruvilla A see Gopalakrishnan R; Thangadurai P
Kuteeva E see Hokfelt T
Kutter CJ see Woodward SH
Kwon JS see Jang JH

L

Labelle A see Remington G
Laffargue P see Vaiva G
LaGrave K see Murphy K
Lahti A see Artaloytia JF
Lajonchere C see Constantino JN
Lalonde JK see Pope HG Jr
Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE, Tam EM: The Can-SAD study: a randomized controlled trial of the effectiveness of light

therapy and fluoxetine in patients with winter seasonal affective disorder. My 805–812
Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB: Prevalence of the metabolic syndrome among patients receiving clozapine. Jy 1273–1276
Landau S see Ettinger U
Lane B see Woodward SH
Lang DJ see Khorram B
Lang J: The Council on Medical Education and Lifelong Learning (off acts). Fe 343–344
Lapitsky L see Adler DA
Laptook RS, Klein DN, Dougherty LR: Ten-year stability of depressive personality disorder in depressed outpatients. My 865–871
Lara C see Borges G
Large MD see Koran LM
Larsen TK see Melle I
Larson T see Anckarsäter H
Lattanzi L, Mungai F, Romano A, Bonuccelli U, Cassano GB, Fagiolini A: Subcutaneous apomorphine for neuroleptic malignant syndrome (letter). Au 1450–1451
Laumonnier F, Roger S, Guérin P, Molinari F, M'Rad R, Cahard D, Belhadj A, Halayem M, Persico AM, Elia M, Romano V, Holbert S, Andres C, Chaabouni H, Colleaux L, Constant J, Le Guennec J-Y, Briault S: Association of a functional deficit of the BKCa channel, a synaptic regulator of neuronal excitability, with autism and mental retardation. Se 1622–1629
Lavori PW see Rush AJ
Lawrence J see Kalsi G
Layde JB, Roberts LW: bk rev, Gazzaniga MS: The Ethical Brain. Ap 751
Lazarus J: The Council on Advocacy and Public Policy (off acts). Fe 337–339
Le Guennec J-Y see Laumonnier F
Lebowitz B see Lieberman JA; Nierenberg AA; Rush AJ; Trivedi MH
Lechan RM, Fekete C: Central mechanisms for thyroid hormone regulation (image, neuro). Se 1492
Lechner SC see Antoni MH
Lee J see Stein A
Lee J-M see Jang JH
Lee JY see Hwang J
Lee K-H, Brown WH, Egleston PN, Green RDJ, Farrow TFD, Hunter MD, Parks RW, Wilkinson ID, Spence SA, Woodruff PWR: A functional magnetic resonance imaging study of social cognition in schizophrenia during an acute episode and after recovery. No 1926–1933
Lee M-B see Lin L
Leff HS see Cook JA
Legatt ME see Foote B
Lehman AF see Cook JA
Lehman RB see Wagner KD
Leibenluft E see Monk CS
Lencz T see DeRosse P
Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Mr 529–531
Lenoci M see Neylan TC
Leonard S, Adams CE: Smoking cessation and schizophrenia (image, neuro). No 1877
Lerner D see Adler DA
Lerner V, Witztum E: Victor Kandinsky, M.D., 1849–1889 (image, psych). Fe 209
Leslie DL see Rosenheck RA
Lesser ML see Robinson DG
Leucht S see Hamann J; Heres S
Leuchter AF see Hunter AM
Levav I see Vicente B
Levav I: Reply to Bosch, van den Noort: Terrorism and health services utilization (letter). De 2198–2199
Levav I, Novikov I, Grinshpoon A, Rosenblum J, Ponizovsky A: Health services utilization in Jerusalem under terrorism. Au 1355–1361
Leventhal BL see Brune CW
Leverich G see Altshuler LL
Leverich GS: Reply to Mattes: Less mood switching with venlafaxine? (letter). Se 1642
Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Fe 232–239
Levine A see Adler CM
Levine J see Amital D
Levine J, Belmaker RH: Osteoporosis and schizophrenia (letter). Mr 549–550
Levinson DF see Mondimore FM
Levitan RD see Lam RW
Levitt AJ see Goldstein BI; Lam RW
Levy NB: bk rev, Roose SP, Sackeim HA, eds: Late-Life Depression. Fe 332
Lewin TJ see Baker A
Lewine R: bk rev, Kingdon DG, Turkington D: Cognitive Therapy of Schizophrenia. Au 1455
Lewis DA see Freedman R; Hariri AR; Hashimoto T; Sibille E
Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Freedman R: Conflict of interest (editorial). Ap 571–573
Lewis G see Torres AR
Lewis J see Dowling FG
Li R see Riccardi P
Li T see Breen G
Li T-K see O'Brien CP
LiCalzi EM see Haznedar MM
Liebenluft E: Flying almost blind (editorial). Jy 1129–1131
Lieber CE see Pardes H
Lieberman JA see Essock SM; McEvoy JP; Merrill DB; Penn DL; Rosenheck RA; Stroup TS
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Hsiao J, Severe J, Lebowitz BD, The CATIE Investigators: Reply to Teich; Basil, Mathews, Adetunji B, Budur K: The CATIE Study (letter). Mr 555–556
Lim KO see Butler PD
Lim KO, Ardekani BA, Nierenberg J, Butler PD, Javitt DC, Hoptman MJ: Voxel-wise correlational analyses of white matter integrity in multiple cognitive domains in schizophrenia. No 2008–2010
Lin C-C see Bai YM
Lin C-Y see Bai YM
Lin DY see Tohen M
Lin H see Rosenheck RA
Lin J-J see Faraone SV
Lin L, Gau SS-F, Lee M-B: Binge eating associated with internal carotid artery aneurysm (letter). Au 1452–1453 (correction, No 2020)
Lin P-I, McInnis MG, Potash JB, Willour V, MacKinnon DF, DePaulo JR, Zandi PP: Clinical correlates and familial aggregation of age at onset in bipolar disorder. Fe 240–246
Lin W see Gilmore JH
Lindberg L see Lindblad F
Lindblad F, Lindberg L, Hjern A: Improved survival in adolescent patients with anorexia nervosa: a comparison of two Swedish national cohorts of female inpatients. Au 1433–1435
Lindborg S see McGlashan TH
Linden D see Wagner KD
Lindley SE see Neylan TC
Lindner S see Vermetten E
Linszen DH see Storosum JG
Liotti M see Pliszka SR
Lipschitz D see Foote B
Liskow B: bk rev, McLaren KD, Martin CD, Hebig P: Psychiatry Clerkship: 150 Biggest Mistakes and How to Avoid Them. No 2023–2024
L'Italien GJ see Olfson M
Liu C-M see Faraone SV
Liu S-K see Faraone SV
Liu W-M see Faraone SV
Livni E see Spencer TJ
Loew TH see Nickel MK
Loewenstein RJ see Vermetten E
Lönnqvist J see Hirvonen J
Lopez V see Kassem L
Lord C see Brune CW
Lorell BS see Robinson DG
Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, DeVane CL, Stowe ZN: Antidepressants in amniotic fluid: another route of fetal exposure. Ja 145–147
Lovel M see Stein A
Lowe TL see Mathews CA
Lu FG: The Council on Minority Mental Health and Health Disparities (off acts). Fe 345–346
Lubin G see Kolevzon A
Lublin H see Rasmussen HB
Lucero L see Roll JM
Luchins D: bk rev, Petryna A, Lakoff A, Kleinman A, eds: Global Pharmaceuticals: Ethics, Markets, Practices. Jy 1301
Lucia LC see Onitsuka T
Luckenbaugh DA see Zarate CA Jr
Lundgren JD see O'Reardon JP
Lundgren JD, Allison KC, Crow S, O'Reardon JP, Berg KC, Galbraith J, Martino NS, Stunkard AJ: Prevalence of the night eating syndrome in a psychiatric population. Ja 156–158
Lundorf MD see Kalsi G

Luther JF see Fava M; McGrath PJ; Nierenberg AA; Rush AJ
Lutter M see Elmquist J
Luty SE see Mulder RT
Lutz M see Constantino JN
Lyketsos CG see Rosenberg PB
Lynch KG see Forman RF
Lyness JM see Pinquart M
Lyoo IK see Hwang J
Lysne DH, Peterson T, Erickson K, Uriell M: The diagnostic and pharmacological variances of bipolar disorder versus attention-deficit/hyperactivity disorder (letter). De 2196

M

MacDonald M see Roll JM
Macgregor S see Forty L
MacKinnon DF see Lin P-I; Mondimore FM
Mackinnon RA see Buckley PJ
Madras BK see Spencer TJ
Maier J see Drozd EM
Maier W see Grabe HJ
Maino K see Heres S
Malhi GS see Berk M
Malhotra AK see DeRosse P; Lencz T
Maltsberger JT see Hendin H
Mamdani MM see Juurlink DN
Mamo D see Remington G
Mamourian AC see Wishart HA
Manji HK see Zarate CA Jr
Mann JJ see Gibbons RD; Parsey RV; Sublette ME; Zalsman G
Mann S see Remington G
Mannaert E see Remington G
Mannuzza S see Terleph TA
Marangell LB see Nierenberg AA; Perlis RH
Marble A see Høglend P
Marcucci C see Sandson NB
Marcus SC see Coyne JC; Olfson M
Marder SR see Davis JM
Marenco S, Steele SU, Egan MF, Goldberg TE, Straub RE, Sharrief AZ, Weinberger DR: Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. Ap 740–742
Margulies DM, Relja M, Carlson GA: bk rev, Dulcan MK, Martini DR, Lake MB: Concise Guide to Child and Adolescent Psychiatry, Third Edition. Se 1651–1652
Marlowe K: Over-optimism of cognitive behavior therapy for schizophrenia (letter). Jy 1294
Marmar CR see Neylan TC
Marrocco M: Report of the Membership Committee (off acts). Se 1661–1662
Marshall N see McDonald C
Marta DH see Mondimore FM
Martin A see Ross DA
Martin A: Stimulating: prescribing amidst controversy (editorial). Ap 574–577
Martin ER see Rabionet R
Martin K see Meyer JH
Martinez MI see Leverich GS
Martinez PE see Grieger TA
Martino NS see Lundgren JD; O'Reardon JP
Mascarenas C see Alvarez CA
Mathews CA, Bimson B, Lowe TL, Herrera LD, Budman CL, Erenberg G, Naarden A, Bruun RD, Freimer NB, Reus VI: Association between maternal smoking and increased symptom severity in Tourette's syndrome. Je 1066–1073
Mathews M see Adetunji B; Basil B
Mathis CM see Friedman SD
Mathur A see Smith EG
Matseoane K see Hasin D
Mattay V see Tan H-Y; Winterer G
Mattes JA: Antabuse reaction with Ceftin (letter). No 2019–2020
Mattes JA: Less mood switching with venlafaxine? (letter). Se 1642
Matthews AM, Fireman M, Zucher B, Sobel M, Hauser P: Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin (case conf). Au 1342–1347
Mayberg HS see Krüger S; Nicolson SE
Mazzoni P see Miller JM
McAllister TW see Wishart HA
McAlonan GM see Page LA
McCague K see Wagner KD
McCann MJ see Roll JM
McCarley RW see Kuroki N; Onitsuka T
McCarthy JF see Valenstein M
McCauley BJ see Swanson JW
McCauley JL see Rabionet R
McClure EB see Monk CS
McCormack J see Robinson DG
McCracken JT see McDougle CJ; McGough JJ
McDonald C see Dempster EL
McDonald C, Marshall N, Sham PC, Bullmore ET, Schulze K, Chapple B, Bramon E, Filbey F, Quraishi S, Walshe M, Murray RM: Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Mr 478–487
McDougle CJ, Scahill L, Aman MG, Arnold LE, McCracken JT, Tierney E, Vitiello B: Reply to Adetunji, Mathews, Osinowo, Williams: Risperidone for the core symptom domains of autism (letter). Mr 551–552
McElhiney MC see Rabkin JG
McElroy SL see Altshuler LL; Leverich GS; Pope HG Jr
McEvoy JP see Lieberman JA; Rosenheck RA; Stroup TS
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swatz MS, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK, CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Ap 600–610
McFarlane AC see Creamer M
McFarlane WR see Cook JA
McGlashan TH see Gunderson JG; Melle I
McGlashan TH: Reply to Block: Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis (letter). Oc 1838
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller J, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Brier A: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. My 790–799
McGlinchey JB see Zimmerman M
McGough JJ, McCracken JT: Adult attention deficit hyperactivity disorder: moving beyond DSM-IV (editorial). Oc 1673–1675
McGrath PJ see Fava M; Nierenberg AA; Rabkin JG; Rush AJ; Taylor BP; Trivedi MH
McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ, STAR*D Study Team: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Se 1531–1541
McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E: Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Se 1542–1548
McGreenery CE see Teicher MH
McGuffin P see Forty L
McInnis MG see Lin P-I; Mondimore FM
McIntyre JS see Freedman R
McKenna K see Constantino JN
McKenzie DP see Creamer M; Kissane DW
McKenzie M see Kissane DW
McLaughlin TJ see Adler DA
McLellan T see Forman RF
McMahon FJ see Kassem L
McNeely HE see Meyer JH
McQuillin A see Kalsi G
Medina-Mora ME see Borges G
Mednick SA see Sørensen HJ
Medori R see Emsley R
Megna JL see Dowling NM
Meijer D see Beasley C
Meijer J see van Os J
Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T: Early detection of the first episode of schizophrenia and suicidal behavior. My 800–804
Meltzer H see Torres AR
Meltzer HY see McEvoy JP
Menard W see Phillips KA
Mendelowitz A see Robinson DG
Mendhekar DN see Duggal HS
Menon V see Tamm L
Menza M see Rosen R
Menza M: STAR*D: the results begin to roll in (editorial). Jy 1123–1125
Menzes P see Stein A
Merikangas KR see Kessler RC
Merrill DB, Ahmari SE, Bradford J-ME, Lieberman JA: Myocarditis during clozapine treatment (case conf). Fe 204–208
Metzler TJ see Neylan TC
Metzner JL see Gold LH
Meyboom RH see Wilting I
Meydan J see Hasin D
Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NPLG, Wilson AA, Houle S: Elevated putamen D2 recep-

tor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Se 1594–1602
Meyer K see Grabe HJ
Meyer-Lindenberg A see Tan H-Y
Micali N, Heyman I: Comorbidity of anxiety with eating disorders and OCD (letter). Fe 326–327
Michalak EE see Lam RW
Michels R see Buckley PJ; Freedman R; Lewis DA
Michels R: bk rev, McHugh PR: The Mind Has Mountains: Reflections on Society and Psychiatry. My 943
Mick E see Faraone SV; Moore CM
Mik H see Beitchman JH
Miklowitz DJ see Nierenberg AA; Perlis RH
Mikulincer M see Solomon Z
Miller AH see Pace TWW
Miller D: Going for the gold (introspections). Ja 13–14
Miller EA see Rosenheck RA
Miller EB see Mondimore FM
Miller IW see Zlotnick C
Miller JD, Pilkonis PA: Neuroticism and affective instability: the same or different? My 839–845
Miller JM, Vorel SR, Tranguch AJ, Kenny ET, Mazzoni P, van Gorp WG, Kleber HD: Anhedonia after a selective bilateral lesion of the globus pallidus (case conf). My 786–788
Miller R see Robinson DG
Miller SC: Language and addiction (letter). No 2015
Miller T see McGlashan TH
Milliken H see Good KP
Mills KL: Reply to Sule, Kelly: Antisocial personality disorder as a confounder in PTSD and substance use disorders (letter). Oc 1840
Mills KL, Teesson M, Ross J, Peters L: Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being. Ap 651–658
Minshew NJ see Hardan AY
Miranda J see Roy-Byrne P
Miresco MJ, Kirmayer LJ: Reply to Mossman, Morse: Mind-brain dualism in psychiatric reasoning (letter). No 2017
Miresco MJ, Kirmayer LJ: The persistence of mind-brain dualism in psychiatric reasoning about clinical scenarios. My 913–918
Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, Oberlander TF: Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Je 1026–1032
Miyahara S see Nierenberg AA
Mletzko TC see Pace TWW
Modai I see Sorkin A
Moffitt TE see Ehrensaft MK; Kim-Cohen J
Mogg K see Monk CS
Mohr S, Brandt P-Y, Borras L, Gilliéron C, Huguelet P: Toward an integration of spirituality and religiousness into the psychosocial dimension of schizophrenia. No 1952–1959
Molinari F see Laumonnier F
Monahan J see Swanson JW
Mondimore FM, Zandi PP, MacKinnon DF, McInnis MG, Miller EB, Crowe RP, Scheftner WA, Marta DH, Weissman MM, Levinson DF, Murphy-Ebenez KP, DePaulo JR Jr, Potash JB: Familial aggregation of illness chronicity in recurrent, early-onset major depression pedigrees. Se 1554–1560
Monk CS, Nelson EE, McClure EB, Mogg K, Bradley BP, Leibenluft E, Blair RJR, Chen G, Charney DS, Ernst M, Pine DS: Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. Je 1091–1097
Monterrubio S, Solowij N: Chronic stress and adaptation (letter). Mr 553
Montgomery JH: Industry funding and author-industry affiliation in clinical trials in psychiatry (letter). Je 1110–1111
Montorsi F see Rosen R
Monuteaux MC see Faraone SV
Moon W-J see Jang JH
Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, Dougherty M, Harpold T, Hammerness P, Randall E, Renshaw PF: Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Fe 316–318
Morehouse R see Lam RW
Moreira-Almeida A, Pietrobon R: Does olanzapine have any antidepressant effect? (letter). Oc 1838–1839
Morey LC see Gunderson JG
Morgan ML see Hunter AM
Morris JC see Csernansky JG
Morris MA see Glaser B
Morrison J see Roffman JL
Morrison JA see Klein DJ
Mors O see Eaton WW; Kalsi G
Morse SJ see Mossman D
Mortensen EL see Sørensen HJ
Mortensen PB see Eaton WW; Webb RT
Mosher PW see Richards AD
Moskowitz C see Kissane DW
Mossman D, Morse SJ: Mind-brain dualism in psychiatric reasoning (letter). No 2017
Moulton JL III see Terleph TA
Moynihan G see Dowling FG
Mpungu SK see Nakimuli-Mpungu E
M'Rad R see Laumonnier F
Muddasani S see Hardan AY
Muderrisoglu S see Westen D
Muehlbacher M see Nickel MK
Mueser KT see Penn DL
Mukamal K see Vaillant GE
Mulder RT, Joyce PR, Frampton CMA, Luty SE, Sullivan PF: Six months of treatment for depression: outcome and predictors of the course of illness. Ja 95–100
Müller N see Seemüller F
Mungai F see Lattanzi L
Muñoz RA: The Council on Global Psychiatry (off acts). Fe 341–342
Munro J see Breen G
Murphy DGM see Page LA
Murphy DGM, Daly E, Schmitz N, Toal F, Murphy K, Curran S, Erlandsson K, Eersels J, Kerwin R, Ell P, Travis M: Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. My 934–936
Murphy-Ebenez KP see Mondimore FM
Murphy JM see Stoddard FJ
Murphy K see Murphy DGM
Murphy K, Dixon V, LaGrave K, Kaufman J, Risinger R, Bloom A, Garavan H: A validation of event-related fMRI comparisons between users of cocaine, nicotine, or cannabis and control subjects. Jy 1245–1251
Murphy KC see Page LA
Murray K see Faraone SV
Murray RM see Dempster EL; Ettinger U; McDonald C
Murrough J see Epstein J
Musisi S see Nakimuli-Mpungu E
Muskin PR: The Council on Psychosomatic Medicine (off acts). Fe 347–348
Musselman DL see Pace TWW
Musso F see Winterer G
Myers JM see Hettema JM
Mykletun A, Overland S, Dahl AA, Krokstad S, Bjerkeset O, Glozier N, Aarø LE, Prince M: A population-based cohort study of the effect of common mental disorders on disability pension awards. Au 1412–1418

N

Naarden A see Mathews CA
Någren K see Hirvonen J
Nakdimen KA: Dissociative disorder underdiagnosed due to undescriptive criteria? (letter). Se 1645
Nakimuli-Mpungu E, Musisi S, Mpungu SK, Katabira E: Primary mania versus HIV-related secondary mania in Uganda. Au 1349–1354
Napolitano B see Robinson DG
Neale MC see Fanous AH; Hettema JM
Neimark G, Hurford MO, DiGiacomo J: The Internet as collateral informant (letter). Oc 1842
Nelson EE see Monk CS
Nelson JC: The STAR*D study: a four-course meal that leaves us wanting more (editorial). No 1864–1866
Nemeroff CB see Geracioti TD Jr; Nicolson SE; Pace TWW
Nemets B see Nemets H
Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH: Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Je 1098–1100
Nestler EJ see Tamminga CA
Newport DJ see Loughhead AM
Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, Lindley SE, Otte C, Schoenfeld FB, Yesavage JA, Marmar CR: No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. De 2186–2188
Nickel C see Nickel MK

Nickel MK, Muehlbacher M, Nickel C, Kettler C, Gil FP, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P: Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. My 833–838
Nicol-Harper R see Stein A
Nicolson SE, Mayberg HS, Pennell PB, Nemeroff CB: Persistent auditory hallucinations that are unresponsive to antipsychotic drugs (case conf). Jy 1153–1159
Niederehe G see McGrath PJ; Nierenberg AA; Rush AJ
Nierenberg AA see Fava M; McGrath PJ; Perlis RH; Rush AJ; Trivedi MH
Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ, STAR*D Study Team: A comparison of lithium and T3 augmentation following two failed medication treatments for depression. a STAR*D report. Se 1519–1530
Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS, STEP-BD Investigators: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Fe 210–216
Nierenberg J see Butler PD; Lim KO
Niklasson L see Anckarsäter H
NIMH Genetics Initiative Bipolar Disorder Consortium see Kassem L
Niznikiewicz MA see Onitsuka T
Nolen WA see Altshuler LL; Leverich GS
Nomura Y see Weissman MM
Nordhaus B see Volkmar FR
Norquist G see Trivedi MH; Zuvekas SH
Norris DM, Price M, Gutheil T, Reid WH: Firearm laws, patients, and the roles of psychiatrists. Au 1392–1396
Nöthen MM see Rietschel M
Novikov I see Levav I
Nowrangi MA see Dunn LB
Nuechterlein KH see Sergi MJ
Nunes E see Hasin D
Nurminen T see Grant JE
Nydén A see Anckarsäter H
Nyegaard M see Kalsi G

O

Oberlander TF see Misri S
O'Boyle MW see Silk TJ
O'Brien CP, Dackis CA, Kampman K: Does modafinil produce euphoria? (letter). Je 1109
O'Brien CP, Volkow N, Li T-K: Reply to Streltzer, Sullivan, Johnson: Addiction versus dependence in pain management (letter). No 2016
O'Brien CP, Volkow N, Li T-K: What's in a word? addiction versus dependence in DSM-V (editorial). My 764–765
O'Donnell BF see Skosnik PD
Ogden RT see Parsey RV
Oh JS see Hwang J
Okazaki Y see Tanii H
Oldham J: bk rev, Yudofsky SC: Fatal Flaws. Je 1115
Oldham JM: Borderline personality disorder and suicidality (treatment in psychiatry). Ja 20–26
Oldham JM: The Council on Quality Care (off acts). Fe 348–350
Olfson M see Wang PS
Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ: Hyperlipidemia following treatment with antipsychotic medications. Oc 1821–1825
Olfson M, Marcus SC, Tedeschi M, Wan GJ: Continuity of antidepressant treatment for adults with depression in the United States. Ja 101–108
Olivares T see Lamberti JS
Olson D see Lamberti JS
O'Malley KD see Barr HM
O'Neill FA see Fanous AH
O'Neill I see Kissane DW
Onitsuka T see Kuroki N
Onitsuka T, Niznikiewicz MA, Spencer KM, Frumin M, Kuroki N, Lucia LC, Shenton ME, McCarley RW: Functional and structural deficits in brain regions subserving face perception in schizophrenia. Mr 455–462
Operskalski B see Simon GE
Opjordsmoen S see Melle I
Oquendo MA see Parsey RV; Sublette ME; Zalsman G
Oral ET, Altinbas K, Demirkiran S: Sudden akathisia after a ziprasidone dose reduction (letter). Mr 546
O'Reardon JP see Lundgren JD
O'Reardon JP, Allison KC, Martino NS, Lundgren JD, Heo M, Stunkard AJ: A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. My 893–898
Ormel J see de Jonge P
Osborne S see Breen G
Osinowo T see Adetunji B
Ostacher MJ see Nierenberg AA; Perlis RH
Otte C see Neylan TC
Otto MW see Perlis RH
Ou-Yang W-C see Faraone SV
Overland S see Mykletun A
Owens MJ see Geracioti TD Jr; Loughhead AM

P

Pace TWW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM: Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Se 1630–1633
Paddock SM see Watkins KE
Pagano ME see Phillips KA
Page LA, Daly E, Schmitz N, Simmons A, Toal F, Deeley PQ, Ambery F, McAlonan GM, Murphy KC, Murphy DGM: An in vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. De 2189–2192
Palmer BW see Dunn LB
Palomo T see Artaloytia JF
Pan H see Epstein J
Pantel J: bk rev, Hirstein W: Brain Fiction: Self-Deception and the Riddle of Confabulation. Mr 559
Parasrampuria DA see Spencer TJ
Pardes H, Lieber CE: Philanthropy for psychiatry (editorial). My 766–767
Parikh S see Krüger S
Park S see Riccardi P
Parker G: Reply to van Strater, Bouvy: Omega-3 fatty acids and mood disorders (letter). No 2018–2019
Parker G, Gibson NA, Brotchie H, Heruc G, Rees A-M, Hadzi-Pavlovic D: Omega-3 fatty acids and mood disorders. Je 969–978 (correction, Oc 1842)
Parker GB: bk rev, Griez EJL, Faravelli C, Nutt DJ, Zohar J, eds: Mood Disorders: Clinical Management and Research Issues. Jy 1304
Parks RW see Lee K-H
Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang Y-y, Simpson N, Arcement J, Huang Y: Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Ja 48–51
Parsey RV, Hastings RS, Oquendo MA, Huang Y-y, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann JJ: Lower serotonin transporter binding potential in the human brain during major depressive episodes. Ja 52–58
Pascual A see Artaloytia JF
Patel JK see Perlis RH
Patel P see Stein A
Patel V, Saraceno B, Kleinman A: Beyond evidence: the moral case for international mental health (editorial). Au 1312–1315
Patterson S: bk rev, Andreasen NC: The Creating Brain: The Neuroscience of Genius. Ja 164–165
Patterson S: bk rev, Didion J: The Year of Magical Thinking. De 2204
Patterson SL see Freedman R
Patterson TL see Bowie CR; Harvey PD
Pavuluri MN, Schenkel LS, Aryal S, Harral EM, Hill SK, Herbener ES, Sweeney JA: Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients. Fe 286–293
Paz RD, Andreasen NC, Daoud SZ, Conley R, Roberts R, Bustillo J, Perrone-Bizzozero NI: Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia. Oc 1829–1831
Pearlstein T see Zlotnick C
Pedersen NL see Kendler KS
Peele R, Razavi M: bk rev, Jensen PS, Knapp P, Mrazek DA: Toward a New Diagnostic System for Child Psychopathology: Moving Beyond the DSM. No 2022–2023
Peirce JM see Roll JM
Peled A see Sorkin A

Penland HR: Lipids, hormones, and gastric bypass (letter). Je 1113
Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA: Reply to Kanas: Group therapy with schizophrenia patients (letter). My 938
Pennell PB see Nicolson SE
Perdereau F see Godart N
Perea E, Robbins BV, Hutto B: Psychosis related to ropinirole (letter). Mr 546–547
Perez R III see Pliszka SR
Pericak-Vance MA see Rabionet R
Perkins DO see Lieberman JA; McEvoy JP; McGlashan TH; Penn DL; Rosenheck RA; Stroup TS
Perlis RH, Brown E, Baker RW, Nierenberg AA: Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Fe 225–231
Perlis RH, Nierenberg AA: Reply to Montgomery: Industry funding and author-industry affiliation in clinical trials in psychiatry (letter). Je 1111
Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder. Fe 217–224
Perrone-Bizzozero NI see Paz RD
Persico AM see Laumonnier F
Peters L see Mills KL
Peterson BS see Amat JA; Gorman DA
Peterson J: bk rev, Dulcan MK, Wiener JM: Essentials of Child and Adolescent Psychiatry. No 2021–2022
Peterson T see Lysne DH
Petkova E see McGrath PJ
Petronis VM see Antoni MH
Petry NM see Roll JM
Petty C see Biederman J; Faraone SV
Phillips K see Antoni MH
Phillips KA, Menard W: Suicidality in body dysmorphic disorder: a prospective study. Jy 1280–1282
Phillips KA, Pagano ME, Menard W, Stout RL: A 12-month follow-up study of the course of body dysmorphic disorder. My 907–912
Phillips ML, Frank E: Redefining bipolar disorder: toward DSM-V (editorial). Jy 1135–1136
Picchioni M see Ettinger U
Pickett-Schenk SA see Cook JA
Pickles AR see Webb RT
Pietrobon R see Moreira-Almeida A
Pilkonis PA see Miller JD
Pilowsky D see Weissman MM
Pincus HA see Wang PS
Pincus HA: bk rev, Richmond JB, Fein R: The Health Care Mess: How We Got Into It and What It Will Take to Get Out. Je 1116
Pindyck LJ see Pope HG Jr
Pine DS see Carter CS; Freedman R; Lewis DA; Monk CS; Terleph TA
Pinquart M, Duberstein PR, Lyness JM: Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Se 1493–1501
Pinta ER: Limitations of study on violent crime and mental illness (letter). De 2193
Piven J see Cascio C
Piwowarczyk L: Reflections about the tsunami (introspections). Oc 1695–1696
Pliszka SR, Glahn DC, Semrud-Clikeman M, Franklin C, Perez R III, Xiong J, Liotti M: Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naive or in long-term treatment. Je 1052–1060
Plotnicov K see Kaye WH
Poe MD see Cascio C; Keefe RSE
Polcari A see Teicher MH
Polsky D, Doshi JA, Bauer MS, Glick HA: Clinical trial-based cost-effectiveness analyses of antipsychotic use. De 2047–2056
Ponizovsky A see Levav I
Pope HG Jr see Kanayama G
Pope HG Jr, Lalonde JK, Pindyck LJ, Walsh T, Bulik CM, Crow SJ, McElroy SL, Rosenthal N, Hudson JI: Binge eating disorder: a stable syndrome. De 2181–2183
Porto R see Rosen R
Poschman K see Smith MV
Post R see Altshuler LL; Leverich GS
Posternak MA see Zimmerman M
Potash JB see Lin P-I; Mondimore FM
Potenza MN see Grant JE
Potter LS see Harvey PD
Prasad KM see Roffman JL
Prata D see Breen G
Preda A see McGlashan TH
Preda A: Do schizophrenia patients want to be involved in their treatment? (letter). My 937
Prescott CA see Hettema JM; Kendler KS
Prestel RS see Woodward SH
Pretty H see Cipriani A
Price Foundation Collaborative Investigators see Kaye WH
Price J see Beasley C
Price LH see Geracioti TD Jr
Price M see Norris DM
Prieto D see Artaloytia JF
Prince M see Mykletun A; Torres AR
Propping P see Rietschel M
Pukrop R see Graae HJ
Puri V see Kalsi G

Q

Querques J see Kontos N
Quesenberry CP Jr see Brown AS
Quiroz JA see Zarate CA Jr
Quitkin FM see McGrath PJ; Taylor BP
Quraishi S see McDonald C

R

Rabin LA see Wishart HA
Rabinowitz J see Emsley R
Rabionet R, McCauley JL, Jaworski JM, Ashley-Koch AE, Martin ER, Sutcliffe JS, Haines JL, DeLong GR, Abramson RK, Wright HH, Cuccaro ML, Gilbert JR, Pericak-Vance MA: Lack of association between autism and SLC25A12. My 929–931
Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ: Placebo-controlled trial of dehydroepiandrosterone for treatment of nonmajor depression in patients with HIV/AIDS. Ja 59–66
Rabkin R see Rabkin JG
Ragland JD see Siegel SJ
Raj YP see Jiang W
Raman PC see Robinson DG
Randall E see Moore CM
Rao A, Keshavan MS: Can psychiatrists recognize mental illness in paintings? (image, psych). Ap 599
Rao N: bk rev, Blazer DG: The Age of Melancholy: "Major Depression" and Its Social Origins. Ap 751–753
Rapaport MH see Freedman R
Raskin S, Teitelbaum A, Zislin J, Durst R: Adjunctive lamotrigine as a possible mania inducer in bipolar patients (letter). Ja 159–160
Rasmussen HB, Timm S, Wang AG, Søeby K, Lublin H, Fenger M, Hemmingsen R, Werge T: Association between the CCR5 32-bp deletion allele and late onset schizophrenia. Mr 507–511
Rassovsky Y see Sergi MJ
Rastam M see Anckarsäter H
Razavi M see Peele R
Razzano LA see Cook JA
Reck C see Grabe HJ
Redelmeier DA see Juurlink DN
Reebye P see Misri S
Rees A-M see Parker G
Rego MD: bk rev, Rabins PV, Lauber L: Getting Old Without Getting Anxious. Au 1457
Reich DB see Zanarini MC
Reichenberg A see Bowie CR; Kolevzon A
Reid WH see Norris DM
Reilly-Harrington NA see Perlis RH
Reinherz HZ, Tanner JL, Berger SR, Beardslee WR, Fitzmaurice GM: Adolescent suicidal ideation as predictive of psychopathology, suicidal behavior, and compromised functioning at age 30. Jy 1226–1232
Reinisch JM see Sørensen HJ
Reiss AL see Tamm L; Woodward SH
Reiss D see Wamboldt MZ
Reiss J see Remington G
Relja M see Margulies DM
Remington G: Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? (editorial). Jy 1132–1134
Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Mr 396–401
Renshaw P see Friedman SD; Hwang J; Moore CM; Woodward SH
Reus VI see Mathews CA

Reus VI: bk rev, Stein DJ, Kupfer DJ, Schatzberg AF, eds: The American Psychiatric Publishing Textbook of Mood Disorders. Oc 1844–1845
Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M: A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Mr 402–410
Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L: Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Oc 1826–1829
Reynolds M see Tarter RE
Rhodes CH see Wishart HA
Riccardi P, Zald D, Li R, Park S, Ansari MS, Dawant B, Anderson S, Woodward N, Schmidt D, Baldwin R, Kessler R: Sex differences in amphetamine-induced displacement of [18F]fallypride in striatal and extrastriatal regions. a PET study. Se 1639–1641
Richards AD, Mosher PW: Abraham Arden Brill, 1874–1948 (image, psych). Mr 386
Richards M, Rubinow DR, Daly RC, Schmidt PJ: Premenstrual symptoms and perimenopausal depression. Ja 133–137
Richmond R see Baker A
Rief W, Henningsen P, Hiller W: Classification of somatoform disorders (letter). Ap 746–747
Rietschel M, Propping P, Nöthen MM: The impact of genetics on psychiatric nosology (letter). De 2197–2198
Riley BP see Fanous AH
Rinehart N see Silk TJ
Rioseco P see Vicente B
Risinger R see Murphy K
Risser R see Tohen M
Ritchie JC see Loughhead AM
Ritz L see Trivedi MH
Roazen P: bk rev, von Unwerth M: Freud's Requiem: Mourning, Memory, and the Invisible History of a Summer Walk. Fe 333–334
Robbins BV see Perea E
Robbins TW see Chamberlain SR
Roberson-Nay R see Terleph TA
Roberts LW see Layde JB
Roberts LW: Ethical philanthropy in academic psychiatry. My 772–778
Roberts LW, Hammond KG, Hoop J: An inverse relationship between perceived harm and participation willingness in schizophrenia research protocols. No 2002–2004
Roberts R see Paz RD
Robinowitz CB: Report of the Secretary-Treasurer: actions of the Board of Trustees (off acts). Se 1655–1656
Robinowitz CB: Report of the Secretary-Treasurer: financial status (off acts). Se 1656–1657
Robinson DG see Lencz T
Robinson DG, Woerner MG, Napolitano B, Raman PC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM: Randomized comparison of olanzapine versus risperidone for the treatment of first episode schizophrenia: 4-month outcomes. De 2096–2102
Robinson RG: Primary mania versus secondary mania of HIV/AIDS in Uganda (editorial). Au 1309–1311
Rodriguez-Vela L see Rosen R
Roffman JL, Simon AB, Prasad KM, Truman CJ, Morrison J, Ernst CL: Neuroscience in psychiatry training: how much do residents need to know? My 919–926
Roger S see Laumonnier F
Rogers WH see Adler DA
Rojas G see Araya R
Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, Blaine J, MacDonald M, DiMaria J, Lucero L, Kellogg S: Contingency management for the treatment of methamphetamine use disorders. No 1993–1999
Romano A see Lattanzi L
Romano V see Laumonnier F
Ronfeldt H see Stoddard FJ
Rose S see Klein DN
Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L, Porto R, Bangerter K, Seger M, Montorsi F, Vardenafil Study Site Investigators: Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the Depression-Related Improvement With Vardenafil for Erectile Response Study. Ja 79–87
Rosenbaum JF see Hirshfeld-Becker DR; Rush AJ
Rosenberg PB, Johnston D, Lyketsos CG: A clinical approach to mild cognitive impairment (treatment in psychiatry). No 1884–1890
Rosenblum J see Levav I
Rosenheck RA see Essock SM; Lieberman JA; McEvoy JP; Stroup TS
Rosenheck R: Integration of mental health care and supported employment (letter). My 940
Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J, CATIE Study Investigators Group: Barriers to employment for people with schizophrenia. Mr 411–417
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin, H, Stroup TS, McEvoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK, Lieberman J, CATIE Study Investigators: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. De 2080–2089
Rosenthal N see Pope HG Jr
Ross CA see Xiao Z
Ross DA, Martin A: bk rev, Geary DC: The Origin of Mind: Evolution of Brain, Cognition, and General Intelligence. Se 1652–1653
Ross J see Mills KL
Ross RG: Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder (treatment in psychiatry). Jy 1149–1152
Roth S: Steven S. Sharfstein, M.D., M.P.A., 132nd President, 2005–2006. Oc 1719
Rother N see Nickel MK
Rother WK see Nickel MK
Roy MD: Mary Mitchell (image, psych). My 789
Roy-Byrne P, Sherbourne C, Miranda J, Stein M, Craske M, Golinelli D, Sullivan G: Poverty and response to treatment among panic disorder patients in primary care. Au 1419–1425
Royal J see Amat JA
Rubia K see Smith AB
Rubin EH: bk rev, Kay J, Silberman EK, Pessar LF: Handbook of Psychiatric Education. My 946
Rubin JEV: Report of the Speaker (off acts). Se 1659–1660
Rubinow A see Amital D
Rubinow DR see Richards M
Rubinow DR: Antidepressant treatment during pregnancy: between Scylla and Charybdis (editorial). Je 954–956
Rück C, Bergström J: Is the Y-BOCS discriminatory against gays and lesbians? (letter). Au 1449 (correction, Oc 1843)
Ruhrmann S see Grabe HJ
Rui Q see Good KP; Khorram B
Ruiz P: Response to the Presidential Address. Oc 1716–1718
Rund BR see Melle I
Ruscio AM see Shear K
Rush AJ see Fava M; McGrath PJ; Nierenberg AA; Trivedi MH
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. No 1905–1917
Rutter M see Kim-Cohen J
Ryan D see Misri S
Ryan ND: bk rev, Morgan GA, Gliner JA, Harmon RJ, Kraemer HC, Leech NL, Vaske JJ: Understanding and Evaluating Research in Applied and Clinical Settings. Ap 754

S

Sabuncuoglu O: Early color illustrations of psychiatric treatment methods, as drawn by physician Serefeddin Sabuncuoglu (1385–1470) (image, psych). De 2071
Sachs GS see Bowden CL; Nierenberg AA; Perlis RH; Tohen M
Sackeim HA see Rush AJ
Sadoff RL: bk rev, Scott CL, Gerbasi JB, eds: Handbook of Correctional Mental Health. Jy 1303–1304
Sagrati S see Meyer JH
Sahakian BJ see Chamberlain SR

St. Clair D see Breen G
Sainz R see Breen G
Saks ER see Dunn LB
Saldivia S see Vicente B
Salganik I, Evgeny S, Galina P: Facilitation in inducing folie a deux through healthy precipitator (letter). Au 1453
Salisbury DF see Kuroki N
Salt J see Brune CW
Saluja S see Amat JA
Samet S see Hasin D
Samson JA see Teicher MH
Samuelson KW see Neylan TC
San L see Reynolds GP
Sanacora G see Geracioti TD Jr
Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R: An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions (case conf). No 1891–1896
Sanislow CA see Gunderson JG
Santulli RB see Wishart HA
Sanz J see Artaloytia JF
Saraceno B see Patel V
Sareen J see Afifi TO
Sassone-Corsi P see Snyder SH
Sato N see Amat JA
Savarino J see Simon GE
Saxe G see Stoddard FJ
Saykin AJ see Wishart HA
Scahill L see McDougle CJ
Schaefer CA see Babulas V; Brown AS
Scheeringa MS, Wright MJ, Hunt JP, Zeanah CH: Factors affecting the diagnosis and prediction of PTSD symptomatology in children and adolescents. Ap 644–651
Scheftner WA see Mondimore FM
Schene AH see de Jonge P
Schenkel LS see Pavuluri MN
Schmahl C see Vermetten E
Schmeidler J see Kolevzon A
Schmidt A see Stein A
Schmidt D see Riccardi P
Schmidt PJ see Richards M
Schmithorst V see Adler CM
Schmitz N see Murphy DGM; Page LA
Schneider F, Gur RC, Koch K, Backes V, Amunts K, Shah NJ, Bilker W, Gur RE, Habel U: Impairment in the specificity of emotion processing in schizophrenia. Mr 442–447
Schoenfeld FB see Neylan TC
Schoevers RA, Smit F, Deeg DJH, Cuijpers P, Dekker J, van Tilburg W, Beekman ATF: Prevention of late-life depression in primary care: do we know where to begin? Se 1611–1621
Schönfeldt-Lecuona C see Wolf RC
Schooler NR see Robinson DG
Schowalter JE see Volkmar FR
Schultz SK see Freedman R; Lewis DA
Schulz SC see White T
Schulze K see Ettinger U; McDonald C
Schulze-Rauschenbach S see Grabe HJ
Schwartz B: The Council on Healthcare Systems and Financing (off acts). Fe 342–343
Scully JH Jr see Freedman R
Scully JH Jr: Report of the Medical Director and CEO (off acts). Se 1657–1659
Secnik K see Kessler RC
Seemüller F, Dehning S, Grunze H, Müller N: Tourette's symptoms provoked by lamotrigine in a bipolar patient (letter). Ja 159
Seger M see Rosen R
Seidman LJ see Biederman J; Walder DJ
Semrud-Clikeman M see Pliszka SR
Senior R see Stein A
Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF: Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Mr 448–454
Seritan AL, Gabbard GO, Benjamin L: War and peace: psychotherapy with a Holocaust survivor (case conf). Oc 1705–1709
Serpe RT see Koran LM
Severe J see Lieberman JA; McEvoy JP; Stroup TS
Sevy S see Lencz T; Robinson DG
Shabsigh R see Rosen R
Shafer M see Cook JA
Shah NJ see Schneider F
Shahlberg O see Anckarsäter H
Shalev AY, Tuval R, Frenkiel-Fishman S, Hadar H, Eth S: Psychological responses to continuous terror: a study of two communities in Israel. Ap 667–673
Sham PC see Dempster EL; McDonald C
Shammi C see Remington G
Shankman SA see Klein DN
Sharfstein SS: Presidential Address: advocacy as leadership. Oc 1712–1715
Sharpe M, Kirmayer L, Kroenke K, Mayou R, Simon G: Reply to Rief, Henningsen, Hiller; Stein: Classification of somatoform disorders (letter). Ap 747–748
Sharrief AZ see Marenco S
Shea MT see Gunderson JG
Shear K, Jin R, Ruscio AM, Walters EE, Kessler RC: Prevalence and correlates of estimated DSM-IV child and adult separation anxiety disorder in the National Comorbidity Survey Replication. Je 1074–1083
Shedler J see Westen D
Sheikh JI see Woodward SH
Shenton ME see Kuroki N; Onitsuka T
Sherbourne C see Roy-Byrne P
Sheridan RL see Stoddard FJ
Shieh M-H see Faraone SV
Shin L see Brown AS
Shirley ER see Abraham PF
Shklar R see Solomon Z
Shockley T see Allison SE
Shores-Wilson K see McGrath PJ; Nierenberg AA; Trivedi MH
Shulman KI see Goldstein BI
Sibille E, Lewis DA: SERT-ainly involved in depression, but when? (editorial). Ja 8–10
Siegel SJ, Irani F, Brensinger CM, Kohler CG, Bilker WB, Ragland JD, Kanes SJ, Gur RC, Gur RE: Prognostic variables at intake and long-term level of function in schizophrenia. Mr 433–441
Siegle GJ, Carter CS, Thase ME: Use of fMRI to predict recovery from unipolar depression with cognitive behavior therapy. Ap 735–738
Sifre T see Antoni MH
Silbersweig DA see Epstein J
Silk KR see Zanarini MC
Silk TJ, Rinehart N, Bradshaw JL, Tonge B, Egan G, O'Boyle MW, Cunnington R: Visuospatial processing and the function of prefrontal-parietal networks in autism spectrum disorders: a functional MRI study. Au 1440–1443
Silverman JM see Kolevzon A
Silvertooth EJ see Jiang W
Sim MR see Creamer M
Simmons A see Page LA
Simon AB see Roffman JL
Simon G see Araya R; Sharpe M
Simon GE see Kessler RC
Simon GE: How can we know whether antidepressants increase suicide risk? (editorial). No 1861–1863
Simon GE, Savarino J, Operskalski B, Wang PS: Suicide risk during antidepressant treatment. Ja 41–47
Simonsen E see Melle I
Simpson N see Parsey RV
Sinclair M see Breen G
Sindelar J see Rosenheck RA
Singh D see Constantino JN
Singh JB see Zarate CA Jr
Singleton N see Torres AR
Sinha R see Brady K
Sinha VK see Desarkar P
Siris SG: A mid-winter night's dream (introspections). No 1883
Siris SG: A tension to detail (introspections). Mr 374–375
Sirot EJ See Feth N
Sjaastad MC see Høglend P
Skodol AE see Gunderson JG
Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O'Donnell BF: Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Oc 1798–1805
Slooff CJ see Tenback DE
Slutske WS: Natural recovery and treatment-seeking in pathological gambling: results of two U.S. national surveys. Fe 297–302
Slutske WS: On the limits of cross-sectional retrospective data for characterizing the course of pathological gambling and its relation with comorbid psychopathology: a reply to Afifi, Cox, and Sareen (letter). Jy 1297–1298
Smals OM see Wilting I
Smeets T, Jelicic M, Merckelbach H: Reduced hippocampal and amygdalar volume in dissociative identity disorder: not such clear evidence (letter). Se 1643
Smit F see Schoevers RA
Smith AB, Taylor E, Brammer M, Toone B, Rubia K: Task-specific hypoactivation in prefrontal and temporoparietal brain regions during motor inhibition and task switching in medication-naive children and adolescents with attention deficit hyperactivity disorder. Je 1044–1051
Smith EG, Mathur A: Blinding in psychotherapy plus medication trials (letter). Jy 1295
Smith GN see Khorram B
Smith HG see Yaeger D
Smith-Lamacchia R see Sandson NB

Smith MV, Poschman K, Cavaleri MA, Howell HB, Yonkers KA: Symptoms of posttraumatic stress disorder in a community sample of low-income pregnant women. My 881–884
Smith RG see Antoni MH; Cascio C
Smits G see Grant JE
Smolen A see Young SE
Smolin Y see Foote B
Snidman N see Stoddard FJ
Snyder SH, Borjigin J, Sassone-Corsi P: Discovering light effects on the brain (image, neuro). My 771
Sobel M see Matthews AM
Södersten P, Bergh C: Comorbidity of anxiety with eating disorders and OCD (letter). Fe 327
Søeby K see Rasmussen HB
SOHO Study Group see Tenback DE
Solomon Z, Mikulincer M: Trajectories of PTSD: A 20-year longitudinal study. Ap 659–666
Solomon Z, Shklar R, Mikulincer M: Reply to Babbar: Frontline treatment of combat stress reaction (letter). Je 1111–1112
Sørbye Ø see Høglend P
Sørensen HJ, Mortensen EL, Reinisch JM, Mednick SA: Early weaning and hospitalization with alcohol-related diagnoses in adult life. Ap 704–709
Sorkin A, Weinshall D, Modai I, Peled A: Improving the accuracy of the diagnosis of schizophrenia by means of virtual reality. Mr 512–520
Sorter M see Klein DJ
Soto-Perello JM see Robinson DG
Spence SA see Hunter MD; Lee K-H
Spencer KM see Onitsuka T
Spencer T see Faraone SV; Kessler RC
Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA, Fischman AJ: PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Mr 387–395
Spiegel D: Recognizing traumatic dissociation (editorial). Ap 566–568
Spiegel D: Reply to Nakdimen: Dissociative disorder underdiagnosed due to undescriptive criteria? (letter). Se 1646
Spiegel D: Reply to Smeets, Jelicic, Merckelbach: Reduced hippocampal and amygdalar volume in dissociative identity disorder: not such clear evidence (letter). No 2014
Spiegel D: Reply to van der Hart, Dorahy: Pierre Janet and the concept of dissociation (letter). Se 1646
Spijkerman TA see de Jonge P
Srinivasaraghavan J: The Council on Social Issues and Public Psychiatry (off acts). Fe 351–352
St-Hilaire A see Docherty NM
Staddon S see Breen G
Stallings MC see Young SE
STAR*D Study Team see McGrath PJ; Nierenberg AA; Trivedi MH
Steele J see Kassem L
Steele SU see Marenco S
Stegman WK see Woodward SH
Stein A, Woolley H, Senior R, Hertzmann L, Lovel M, Lee J, Cooper S, Wheatcroft R, Challacombe F, Patel P, Nicol-Harper R, Menzes P, Schmidt A, Juszczak E, Fairburn CG: Treating disturbances in the relationship between mothers with bulimic eating disorders and their infants: a randomized, controlled trial of video feedback. My 899–906
Stein E: Classification of somatoform disorders (letter). Ap 747
Stein M see Roy-Byrne P
STEP-BD Investigators see Nierenberg AA
Stern E see Epstein J
Stewart JW see McGrath PJ; Rush AJ; Taylor BP
Stewart LP see Woodward SH
Stinson FS see Compton WM
Stitzer ML see Roll JM
Stoddard FJ, Ronfeldt H, Kagan J, Drake JE, Snidman N, Murphy JM, Saxe G, Burns J, Sheridan RL: Young burned children: the course of acute stress and physiological and behavioral responses. Je 1084–1090
Stone MH: Relationship of borderline personality disorder and bipolar disorder (editorial). Jy 1126–1128
Stonnington CM, Barry JJ, Fisher RS: Conversion disorder (case conf). Se 1510–1517
Storosum JG, Wohlfarth T, Gispen-de Wied CC, Linszen DH, Gersons BPR, van Zwieten BJ, van den Brink W: Reply to Goldney: Suicide risk in placebo-controlled trials of bipolar disorder (letter). Fe 329
Stout RL see Gunderson JG; Phillips KA
Stowe ZN see Loughhead AM
Strain EC: The Council on Addiction Psychiatry (off acts). Fe 337
Strakowski SM see Adler CM
Straub RE see Marenco S
Strauss ME see Docherty NM
Strawn JR see Geracioti TD Jr
Streeter CC see Woodward SH
Streissguth AP see Barr HM
Streltzer J, Johansen L: Prescription drug dependence and evolving beliefs about chronic pain management (case conf). Ap 594–598
Streltzer J, Johansen L: Reply to Abramson: Opiate treatment for patients in chronic non-cancer pain (letter). Jy 1299
Streltzer J, Johansen L: Reply to Fishbain, Gallagher: Comments on "Prescription drug dependence and evolving beliefs about chronic pain management" (letter). De 2195
Streltzer J, Sullivan CR, Johnson B: Addiction versus dependence in pain management (letter). No 2016
Strohmayer E see Epstein J
Stroup TS see Essock SM; Lieberman JA; McEvoy JP; Rosenheck RA
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK, CATIE Investigators: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Ap 611–622
Strous RD: Nazi euthanasia of the mentally ill at Hadamar (image, psych). Ja 27
Stunkard AJ see Lundgren JD; O'Reardon JP
Styner M see Cascio C
Su J see Faraone SV; Walder DJ
Su T-P see Bai YM
Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ: Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Je 1100–1102
Sule A, Kelly KI: Antisocial personality disorder as a confounder in PTSD and substance use disorders (letter). Oc 1840
Sullivan CR see Streltzer J
Sullivan G see Roy-Byrne P
Sullivan PF see Mulder RT
Sunder KR see Bodnar LM
Suppes T see Altshuler LL; Leverich GS
Susser ES see Brown AS
Sust S see Tan H-Y
Sutcliffe JS see Rabionet R
Swann AC: What is bipolar disorder? (editorial). Fe 177–179
Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA, Ferron J, Wagner HR, McCauley BJ, Kim M: Facilitated psychiatric advance directives: a randomized trial of an intervention to foster advance treatment planning among persons with severe mental illness. No 1943–1951
Swanson JW, Van Dorn RA, Monahan J, Swartz MS: Violence and leveraged community treatment for persons with mental disorders. Au 1404–1411
Swartz MS see Lieberman JA; McEvoy JP; Rosenheck RA; Stroup TS; Swanson JW
Sweeney JA see Pavuluri MN
Sweeney P see Zlotnick C
Szanto K see Hendin H

T

Talbott JA: bk rev, Bodanis D: Passionate Minds: The Great Enlightenment Love Affair. De 2203–2204
Tam EM see Lam RW
Tamm L, Menon V, Reiss AL: Parietal attentional system aberrations during target detection in adolescents with attention deficit hyperactivity disorder: event-related fMRI evidence. Je 1033–1043
Tamminga CA see Davis JM; Freedman R; Lewis DA
Tamminga CA: HIV and AIDS (image, neuro). Au 1322
Tamminga CA: Practical treatment information for schizophrenia (editorial). Ap 563–565

Tamminga CA: The anatomy of fear extinction (image, neuro). Je 961

Tamminga CA, Nestler EJ: Pathological gambling: focusing on the addiction, not the activity (editorial). Fe 180–181

Tan H-Y, Sust S, Buckholtz JW, Mattay VS, Meyer-Lindenberg A, Egan MF, Weinberger DR, Callicott JH: Dysfunctional prefrontal regional specialization and compensation in schizophrenia. No 1969–1977

Tandon R: Comparing antipsychotic efficacy (letter). Se 1645

Tang W see Lamberti JS

Tanii H, Fujita K, Okazaki Y: Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal (letter). Mr 547–548

Tanner JL see Reinherz HZ

Tarter RE, Vanyukov M, Kirisci L, Reynolds M, Clark DB: Predictors of marijuana use in adolescents before and after licit drug use: examination of the gateway hypothesis. De 2134–2140

Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H, Quitkin FM: Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Ja 73–78

Taylor E see Smith AB

Taylor M see Bhagwagar Z

Taylor MA see Fink M

Taylor RL see Baker A

Tedeschi M see Olfson M

Teesson M see Mills KL

Teich J: The CATIE Study (letter). Mr 554–555

Teicher MH, Samson JA, Polcari A, McGreenery CE: Sticks, stones, and hurtful words: relative effects of various forms of childhood maltreatment. Je 993–1000

Teitelbaum A see Raskin S

Templeman LA see Reynolds GP

Tenback DE, van Harten PN, Slooff CJ, van Os J, SOHO Study Group: Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. Au 1438–1440

Terao T: Comment on "What happened to lithium?: antidepressant augmentation in clinical settings" (letter). De 2196–2197

Terleph TA, Klein RG, Roberson-Nay R, Mannuzza S, Moulton JL III, Woldehawariat G, Guardino M, Pine DS: Stress responsivity and HPA axis activity in juveniles: results from a home-based CO2 inhalation study. Ap 738–740

Terman JS see Terman M

Terman M, Terman JS: Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder. De 2126–2133

Thai V see Fainsinger RL

Thakur A see Desarkar P

Thangadurai P, Jyothi KS, Gopalakrishnan R, Kuruvilla A, Jacob KS: Reversible neutropenia with olanzapine following clozapine-induced neutropenia (letter). Jy 1298

Thase ME see Fava M; McGrath PJ; Nierenberg AA; Perlis RH; Rush AJ; Siegle GJ

Thomas M see Freedman R

Thomas P see Vaiva G

Thombs BD, Grace SL, Ziegelstein RC: Do symptom dimensions of depression following myocardial infarction related differently to physical health indicators and cardiac prognosis? (letter). Jy 1295–1296

Thompson TR see Bowden CL

Thornton L see Kaye WH

Tieman W, van der Ende J, Verhulst FC: Reply to Goldney: On intercountry adoptions (letter). Ja 162

Tierney E see McDougle CJ

Tiihonen J: Fatal agranulocytosis 4 years after discontinuation of clozapine (letter). Ja 161

Timm S see Rasmussen HB

Timmerman I see Alvarez CA

Toal F see Murphy DGM; Page LA

Todd RD see Constantino JN

Tohen M see McGlashan TH

Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC-Y, Bowden CL: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Fe 247–256

Tohen M, Lin DY: Reply to Moreira-Almeida, Pietrobon: Does olanzapine have any antidepressant effect? (letter). Oc 1839

Tomás MP see Kim-Cohen J

Tonge B see Silk TJ

Toone B see Smith AB

Toprac MG see Cook JA

Toren P see Reyes M

Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N: Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. No 1978–1985

Torres S see Vicente B

Toulopoulou T see Dempster EL; Ettinger U

Towbin KE: Gaining: pediatric patients and use of atypical antipsychotics (editorial). De 2034–2036

Tranguch AJ see Miller JM

Travis M see Murphy DGM

Trivedi MH see McGrath PJ; Nierenberg AA; Rush AJ

Trivedi MH, Rush AJ, Fava M, Wisniewski SR: Reply to Hierholzer: Remission rates for depression in STAR*D study (letter). Jy 1293–1294

Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Ja 28–40

Truman CJ see Roffman JL

Trzaskoma Q see McGlashan TH

Tsuang M-M see Faraone SV

Tsuang MT see Faraone SV

Tu X see Lamberti JS

Tuomari AV see Olfson M

Turkington D: Reply to Kontos, Freudenreich, Querques: Using a medical model with psychotic patients (letter). Se 1647

Turkington D: Reply to Marlowe: Over-optimism of cognitive behavior therapy for schizophrenia (letter). Jy 1294–1295

Turkington D, Kingdon D, Weiden PJ: Cognitive behavior therapy for schizophrenia. Mr 365–373

Tuunainen A see Kripke DF

Tuval R see Shalev AY

Twito T: Chief complaint (introspections). Se 1502–1503

U

Uhde TW see Cortese BM

Uher R, Jones HM: Hallucinations during lamotrigine treatment of bipolar disorder (letter). Ap 749–750

Urcuyo KR see Antoni MH

Uriell M see Lysne DH

Ursano RJ see Grieger TA

Ustun TB see Kessler RC

Usui C see Doi N

V

Vaglum P see Melle I

Vaillant GE: bk rev, Wagner PS, Spiro C: Divided Minds. Mr 557–558

Vaillant GE, DeRago AC, Mukamal K: Natural history of male psychological health, XV: retirement satisfaction. Ap 682–688

Vaiva G, Boss V, Ducrocq F, Fontaine M, Devos P, Brunet A, Laffargue P, Goudemand M, Thomas P: Relationship between posttrauma GABA plasma levels and PTSD at 1-year follow-up. Au 1446–1448

Valenstein M: Keeping our eyes on STAR*D (editorial). Se 1484–1486

Valenstein M: Reply to Terao: Comment on "What happened to lithium?: antidepressant augmentation in clinical settings" (letter). De 2197

Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC: What happened to lithium? antidepressant augmentation in clinical settings. Jy 1219–1225 (correction, Se 1648)

van den Berg MP see de Jonge P

van den Brink W see Storosum JG

van den Brinnk RHS see de Jonge P

van den Noort M see Bosch P

van den Oord EJ see Fanous AH

van der Ende J see Tieman W

van der Hart O, Dorahy M: Pierre Janet and the concept of dissociation (letter). Se 1646

Van Dorn RA see Swanson JW

Van Eerdewegh P see Faraone SV

van Erp TGM see Hirvonen J

van Gorp WG see Miller JM

van Harten PN see Tenback DE
Van Heertum RL see Parsey RV
van Melle JP see de Jonge P
van Os J see Tenback DE
van Os J, Drukker M, à Campo J, Meijer J, Bak M, Delespaul P: Validation of remission criteria for schizophrenia. No 2000–2002
van Strater ACP, Bouvy PF: Omega-3 fatty acids and mood disorders (letter). No 2018
van Tilburg W see Schoevers RA
van Veldhuisen DJ see de Jonge P
van Zwieten BJ see Storosum JG
Vandorpe RA see Khorram B
Vanyukov M see Tarter RE
Vardenafil Study Site Investigators see Rosen R
Vasantharaj B see Gopalakrishnan R
Veenhuis PE: bk rev, van Pragg HM, de Kloet R, van Os J: Stress, the Brain, and Depression. Jy 1301–1302
Vemulapalli M see Hardan AY
Verdeli H see Weissman MM
Vergare MJ: The Council on Member and District Branch Relations (off acts). Fe 344–345
Verhoeff NPLG see Meyer JH
Verhulst FC see Tieman W
Vermetten E: Reply to Smeets, Jelicic, Merckelbach: Reduced hippocampal and amygdalar volume in dissociative identity disorder: not such clear evidence (letter). Se 1643–1644
Vermetten E, Schmahl C, Lindner S, Loewenstein RJ, Bremner JD: Hippocampal and amygdalar volumes in dissociative identity disorder. Ap 630–636
Vicente B, Kohn R, Rioseco P, Saldivia S, Levav I, Torres S: Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile Psychiatric Prevalence Study. Au 1362–1370
Vishne T see Amital D
Vitiello B see McDougle CJ; Zuvekas SH
Volkmar FR, Nordhaus B, Schowalter JE: Albert J. Solnit (image, psych). Je 992
Volkow N see O'Brien CP
Volkow ND: Stimulant medications: how to minimize their reinforcing effects? (editorial). Mr 359–361
von Wahlde L see Allison SE
Vorel SR see Miller JM

W

Wagner HR see Swanson JW
Wagner KD: Reply to Lysne, Peterson, Erickson, Uriell: The diagnostic and pharmacological variances of bipolar disorder versus attention-deficit/hyperactivity disorder (letter). De 2196
Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, D'Souza J, Wamil A, Lehman RB, Berv D, Linden D: A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Jy 1179–1186 (correction, Oc 1843)
Wagner M see Grabe HJ
Wahl DS: Report of the Elections Committee (off acts). Se 1663
Wain HJ see Grieger TA
Wald LL see Woodward SH
Walder DJ, Seidman LJ, Cullen N, Su J, Tsuang MT, Goldstein JM: Sex differences in language dysfunction in schizophrenia. Mr 470–477
Waldheter EJ see Penn DL
Walker TM see Keefe RSE
Wallerstein RS: bk rev, Auchinbcloss EL, ed: The Quiet Revolution in American Psychoanalysis: Selected Papers of Arnold Cooper. No 2021 (correction, De 2199)
Walsh D see Fanous AH
Walsh T see Pope HG Jr
Walshe M see Dempster EL; McDonald C
Walters E see Borges G
Walters EE see Kessler RC; Shear K
Wamboldt MZ, Reiss D: Explorations of parenting environments in the evolution of psychiatric problems in children (editorial). Je 951–953
Wamil A see Wagner KD
Wan GJ see Olfson M
Wang AG see Rasmussen HB
Wang L see Andrews J; Csernansky JG
Wang PS see Borges G; Kessler RC; Simon GE
Wang PS, Demler O, Olfson M, Pincus HA, Wells KB, Kessler RC: Changing profiles of service sectors used for mental health care in the United States. Jy 1187–1198
Wang Z see Xiao Z
Warden D see Fava M; McGrath PJ; Nierenberg AA; Rush AJ; Trivedi MH
Wardrop M see Moore CM
Warner R: bk rev, Whitwell D: Recovery Beyond Psychiatry. Se 1651
Warner V see Weissman MM
Waslick B: Carbamazepine and pediatric bipolar disorder (letter). De 2195
Watkins KE, Paddock SM, Zhang L, Wells KB: Improving care for depression in patients with comorbid substance misuse. Ja 125–132
Waxman R see Hasin D
Webb M: bk rev, Bandelow B, Stein DJ, eds: Social Anxiety Disorder. Oc 1845
Webb RT, Abel KM, Pickles AR, Appleby L, King-Hele SA, Mortensen PB: Mortality risk among offspring of psychiatric inpatients: a population-based follow-up to early adulthood. De 2170–2177
Weber MM see Engstrom EJ
Weiden PJ see Turkington D
Weinberg I see Gunderson JG
Weinberger DR see Marenco S; Tan H-Y; Winterer G
Weinshall D see Sorkin A
Weiser M see Kolevzon A
Weissman MM see Mondimore FM
Weissman MM, Wickramaratne P, Nomura Y, Warner V, Pilowsky D, Verdeli H: Offspring of depressed parents: 20 years later. Je 1001–1008
Weith J see Yohanan M
Wells KA see Antoni MH
Wells KB see Wang PS; Watkins KE
Wentz E see Anckarsäter H
Werge T see Rasmussen HB
Westen D, Muderrisoglu S: Clinical assessment of pathological personality traits. Jy 1285–1287
Westen D, Shedler J, Bradley R: A prototype approach to personality disorder diagnosis. My 846–856
Westergren S see Anckarsäter H
Westling BE see Carlbring P
Wheatcroft R see Stein A
White RL see Bowden CL
White T, Anjum A, Schulz SC: The schizophrenia prodrome (treatment in psychiatry). Mr 376–380
Whitehorn D see Good KP
Wickham H see Dempster EL
Wickramaratne P see Weissman MM
Wiener K see Lamberti JS
Wilcox RE see Erickson CK
Wilens TE see Wagner KD
Wilens TE: Attention deficit hyperactivity disorder and substance use disorders (treatment in psychiatry). De 2059–2063
Wilhelm K see Baker A
Wilkinson ID see Hunter MD; Lee K-H
Williams A see Adetunji B
Williams GC see Lamberti JS
Willour V see Lin P-I
Wilson AA see Meyer JH
Wilting I, Smals OM, Holwerda NJ, Meyboom RH, De Bruin ML, Egberts TCG: QTC prolongation and torsades de pointes in an elderly woman taking fluoxetine (letter). Fe 325
Wimberly SR see Antoni MH
Winterer G, Musso F, Beckmann C, Mattay V, Egan MF, Jones DW, Callicott JH, Coppola R, Weinberger DR: Instability of prefrontal signal processing in schizophrenia. No 1960–1968
Wishart HA, Saykin AJ, Rabin LA, Santulli RB, Flashman LA, Guerin SJ, Mamourian AC, Belloni DR, Rhodes CH, McAllister TW: Increased brain activation during working memory in cognitively intact adults with the APOE e4 allele. Se 1603–1610
Wisner KL see Bodnar LM
Wisniewski SR see Fava M; McGrath PJ; Nierenberg AA; Perlis RH; Rush AJ; Trivedi MH
Witzum E see Lerner V
Woerner MG see Lencz T; Robinson DG
Wohlfarth T see Storosum JG
Woldehawariat G see Terleph TA
Wolf RC, Schönfeldt-Lecuona C: Depressive symptoms as first manifestation of posterior cortical atrophy (letter). My 939–940
Wood WC: Report of the Committee on Bylaws (off acts). Se 1660–1661
Woodruff PWR see Lee K-H
Woods SW see McGlashan TH
Woodward N see Riccardi P
Woodward SH, Kaloupek DG, Streeter CC, Kimble MO, Reiss AL, Eliez S, Wald LL, Renshaw PF, Frederick BB, Lane B, Sheikh JI, Stegman WK, Kutter CJ, Stewart LP, Prestel RS, Arsenault NJ: Hippocampal volume, PTSD, and alcoholism in combat veterans. Ap 674–681
Woody GE see Forman RF
Woolley H see Stein A

Wozniak J see Moore CM
Wozniak PJ see Allen MH
Wright HH see Rabionet R
Wright MJ see Scheeringa MS

X

Xiao Z, Yan H, Wang Z, Zou Z, Xu Y, Chen J, Zhang H, Ross CA, Keyes BB: Trauma and dissociation in China. Au 1388–1391
Xiong C see Csernansky JG
Xiong J see Pliszka SR
Xu K see Lencz T
Xu Y see Xiao Z

Y

Yaeger D, Smith HG, Altshuler LL: Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum (case conf). De 2064–2070
Yan H see Xiao Z
Yang Y see Epstein J
Yashaswi V see Dowling NM
Yen S see Gunderson JG
Yesavage JA see Neylan TC
Yohanan M, Aulakh JS, Weith J, Hawkins JW: Pisa syndrome in a patient in a wheelchair taking valproic acid (letter). Fe 325–326
Yonkers KA see Smith MV
Young EA see Valenstein M
Young LT see Krüger S
Young SE, Smolen A, Hewitt JK, Haberstick BC, Stallings MC, Corley RP, Crowley TJ: Interaction between MAO-A genotype and maltreatment in the risk for conduct disorder: failure to confirm in adolescent patients. Je 1019–1025
Yudofsky SC see Freedman R
Yurgelun-Todd D see Kuroki N

Z

Zacher JL, Hatchett AD: Aripiprazole-induced movement disorder (letter). Ja 160–161
Zald D see Riccardi P
Zalsman G, Huang Y, Oquendo MA, Burke AK, Hu X, Brent DA, Ellis SP, Goldman D, Mann JJ: Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Se 1588–1593
Zanarini MC see Gunderson JG
Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR: Prediction of the 10-year course of borderline personality disorder. My 827–832
Zandi P see Kassem L; Lin P-I; Mondimore FM
Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Ja 153–155
Zaslavsky AM see Kessler RC
Zeanah CH see Scheeringa MS
Zeller S: Emergency psychiatry in Houston: caring for victims of the Katrina catastrophe (introspections). My 779–780
Zhang H see Perlis RH; Xiao Z
Zhang L see Watkins KE
Zhong K see Harvey PD
Zhu H see Amat JA; Gorman DA
Zhu Y see Gharabawi GM
Ziegelstein RC see Thombs BD
Zigman J see Elmquist J
Zimmerman M see First MB
Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D: How should remission from depression be defined? The depressed patient's perspective. Ja 148–150
Zipursky RB see McGlashan TH
Zislin J see Raskin S
Zlotnick C, Miller IW, Pearlstein T, Howard M, Sweeney P: A preventive intervention for pregnant women on public assistance at risk for postpartum depression. Au 1443–1445
Zou Z see Xiao Z
Zucker B see Matthews AM
Zuvekas SH, Vitiello B, Norquist GS: Recent trends in stimulant medication use among U.S. children. Ap 579–585 (correction, My 942)